Podcasts about Metformin

The 3 "Longevity Drugs" That Fail the Data, and 4 Repurposed Ones Worth Considering Back with another solo episode, this one on Big Pharma! Metformin, rapamycin, and statins are three of the most trusted names in longevity, and none of them hold up the way you've been told. This episode breaks down the human data behind the drugs everyone assumes are safe, and reveals four lesser-known repurposed pharmaceuticals that might do more for your metabolism, mitochondria, and lifespan. Watch this episode on YouTube for the full video experience: https://www.youtube.com/@DaveAspreyBPR Dave walks through why metformin blunts the muscle-building signal your body needs from exercise, why rapamycin's stunning mouse studies fell apart in the 2025 PEARL trial, and why statins help one person in a hundred while draining the CoQ10 your mitochondria depend on. Then he lays out the yes list: tadalafil for vascular and brain health, SGLT2 inhibitors for metabolic and kidney protection, acarbose for gut and longevity markers, and low dose naltrexone for calming an overactive immune system. Host Dave Asprey is the father of biohacking, founder of Danger Coffee and Smarter Not Harder, and a New York Times bestselling author who has spent decades studying human performance, functional medicine, and the science of not aging. As co-founder of Unlimited.Life, a concierge longevity practice that runs over $50,000 in lab work per client, he pulls back the curtain on what the data actually shows once you strip away the marketing. This is essential listening for anyone serious about biohacking, longevity, anti-aging, human performance, brain optimization, and hacking their own biology with real supplements and functional medicine tools instead of guesswork. You'll Learn: Why metformin can cancel out the muscle gains from resistance training and drain your B12 for years What the 2025 PEARL trial actually found when rapamycin was tested in healthy adults Why statins carry a 100-to-1 harm-to-benefit ratio and quietly starve your mitochondria of CoQ10 How tadalafil supports nitric oxide, vascular health, and neuroplasticity at low daily doses Why SGLT2 inhibitors trigger ketosis-like metabolic effects and protect kidney function How acarbose changes gut bacteria and shows some of the strongest longevity data in mouse studies How low dose naltrexone modulates the immune system and reduces neuroinflammation How to talk to your doctor about using these drugs off-label for longevity instead of disease treatment Thank you to our sponsors! - ALP | Go to alppouch.com, code DAVE for 10% off. - Timeline | Visit timeline.com/dave and get up to 20% off when you subscribe and save. - Kinetic | Instead of pushing your system harder, Kenetik feeds your brain the ketones it craves to fuel calm clarity and steady focus. Go to drinkkenetik.com/DAVE and use code DAVE for a discount. - Visit www.myvitalc.com/davesfav to unlock Dave's discount Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade brings you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights inhealth, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence, and conscious living. New episodes are released every Tuesday, Thursday, Friday, and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: Metformin, Rapamycin, Statins, Tadalafil, Cialis, SGLT2 inhibitors, Jardiance, Acarbose, low dose naltrexone, longevity drugs, anti-aging medication, repurposed pharmaceuticals, off-label drugs, mTOR inhibitor, AMPK, autophagy, endothelial dysfunction, CoQ10, insulin resistance, mitochondrial efficiency, senescent cells, nitric oxide, neuroinflammation, vascular health, PEARL trial, Unlimited.Life Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15? • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Trailer 01:01 – Intro 03:48 – Metformin 09:18 – Rapamycin 12:55 – Statins 17:28 – Statins & CoQ10 19:38 – Tadalafil 23:43 – SGLT2 Inhibitors 26:12 – Acarbose 28:40 – Low-Dose Naltrexone (LDN) 31:44 – Dosing & Recap See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more... Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  On this episode of Diabetes Connections In the news… The FDA approves a new indication and health benefit for Mounjaro, lots of CGM news including an update on Medicare coverage for people who don't use insulin and a new study about using CGM when you don't have diabetes, metformin and aging, statins and type 2, and did you know there was a Dolly Parton diabetes connections? That and much more.. that's coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Welcome to September! Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved – more on that coming up. But please register – the link is in the show notes. So much going on over here – tomorrow night we have our Club 1921 in Charlotte, later this month Moms' Night Out Detroit/Bloomfield and in October we're going to Seattle. Please join us. More at d-c dot com slash events. Okay.. our top story this week: XX Another indication for Mounjaro – the FDA approved it to lower the risk of major adverse cardiovascular (CV) events (MACE), including CV death, non-fatal heart attack, or non-fatal stroke in adults with type 2 diabetes who are at high risk for these events. Mounjaro – the brand name of tirzepatide - is already approved as an adjunct to diet and exercise to improve blood sugar in adults and children 10 years of age and older with type 2 diabetes. The approval was based on results from the largest and longest tirzepatide study to date, enrolling more than 13,000 participants across 30 countries over more than four and a half years. In the trial, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), a GLP-1 treatment with established cardiovascular benefit, with an 8% lower rate of cardiovascular death, heart attack or stroke (MACE-3). The estimated hazard ratio for time to first MACE was 0.92 (95.3% CI: 0.83, 1.01) for Mounjaro compared to Trulicity (dulaglutide). https://www.prnewswire.com/news-releases/fda-approves-lillys-mounjaro-tirzepatide-to-reduce-cardiovascular-risk-in-adults-with-type-2-diabetes-302862415.html XX The FDA approves the Libre Duo – the first device designed to continuously monitor both blood sugar levels and ketone levels in people with diabetes. The Libre Duo 10-Day Continuous Dual Glucose Ketone Monitoring System is now approved for those ages 2 and older. Until now, the agency said, people had to monitor ketone levels with separate tests that only provided a single measurement at one point in time. The new system combines blood sugar and ketone tests and monitors them continuously. Readings -- and alerts in case of dangerous trends -- are sent wirelessly to a smartphone app. The FDA previously granted "breakthrough device" status to the system, which is meant to expedite the device's development and review. https://www.upi.com/Top_News/US/2026/08/25/fda-oks-blood-sugar-ketone-monitor/5521787688375/ XX Diabetes tech firms Dexcom and Abbott are watching closely for a Medicare coverage expansion that could significantly broaden access to their glucose sensors. The Centers for Medicare and Medicaid Services is expected to expand Medicare coverage of continuous glucose monitors to people with diabetes who do not take insulin. Currently, coverage is limited to people with Type 1 or Type 2 diabetes who take insulin or have a history of problematic low blood sugar. Dexcom CEO Jake Leach told investors in a late July earnings call that the company expects to hear back from the CMS before the end of the year, with coverage going into effect in mid-2027.     Dexcom presented results of a randomized, controlled trial earlier this summer at the American Diabetes Association's Scientific Sessions that it expects will support the CMS' decision. The 26-week study found that people who used a CGM had a larger hemoglobin A1C reduction than the control group and spent five more hours per day in a normal glucose range than the control group. https://www.medtechdive.com/news/dexcom-abbott-await-medicare-coverage-expansion-for-cgms/828775/ XX A new study suggests continuous glucose monitors (CGMs) may offer benefits for people with type 1 diabetes that go beyond improving blood sugar and reducing hypoglycemia.   Researchers analyzed health records from more than 8,400 adults with type 1 diabetes receiving care through the Veterans Health Administration. Over one to four years of follow-up, people who started using a CGM had a 10% to 16% lower risk of death from any cause compared with those who did not use one.   The association appeared strongest among people over age 65 and those who were not using insulin pumps. Researchers did not find meaningful differences based on A1C, race or ethnicity, or frailty.   Importantly, this was an observational study using medical records, not a randomized clinical trial, so it cannot prove that CGM use directly caused the lower death rate. But the findings suggest CGM may have important long-term health benefits beyond glucose management.https://visualize.jove.com/42319755-continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-onset-type-1-diabetes-patients-a-target-trial-emulation-study-within-the-veterans-health-administration XX We've been talking about people without diabetes using CGMs for a long time.. now a new study weighs in. Research published in JAMA finds that this wellness trend isn't helpful for people without a diabetes diagnosis. They found that the strongest evidence for CGM use is for people who are already living with diabetes, but not for those without the condition who use them for wellness purposes. It's also worth noting, though, that this new study is a narrative review. This means that the researchers drew their conclusions from the findings reported in several other studies. More randomized controlled trials would be necessary to see whether there are any meaningful health benefits of using a CGM if you don't have diabetes.   Dower also warned that constantly monitoring your blood sugar when you don't have diabetes could lead to unintended health anxiety. In some cases, you may even make accidental lifestyle changes that could be harmful. "[Blood sugar] spikes may occur after meals, but if this leads someone to replace healthy food such as fruit with unhealthy food such as something high in fat but low in carbohydrate, the glucose information has done more harm than good," Dower said. https://www.verywellhealth.com/blood-sugar-monitor-for-people-without-diabetes-12058575   XX   Could metformin somehow influence the biological processes that drive aging? A new review found evidence that metformin may affect several key features of aging, including how cells use energy, inflammation, cellular damage and even some changes in gene activity. Animal studies have shown longer lifespans or improvements in markers of biological aging, while some human studies have also found promising results.   But researchers say there's still no proof that metformin actually slows aging or helps healthy people live longer. Most human research has involved people with diabetes or other health conditions, and one large trial found that while metformin helped prevent type 2 diabetes, it did not reduce cancer, cardiovascular disease or deaths.   Researchers say larger clinical trials in people without diabetes are needed to determine whether metformin can truly extend healthy lifespan—or whether its benefits are primarily related to preventing and treating specific diseases. https://www.technologynetworks.com/drug-discovery/news/metformin-may-influence-longevity-through-the-gut-microbiome-and-epigenetic-changes-416035 XX More to come including more research on a spice thought to help diabetes, predictions about the number of people who may be living with type 1 in the years to come around the world, and a connection I didn't know about between diabetes and Dolly Parton.   XX A compound found in turmeric may help protect blood vessels from some of the damage caused by Type 1 diabetes. In rats, curcumin reduced inflammation, improved cellular signaling, and restored vascular health to levels resembling those of nondiabetic animals. The results hint at a possible new way to reduce the long-term cardiovascular risks of diabetes, but human trials are still needed. Curcumin, the natural compound responsible for turmeric's vivid yellow color, is widely studied for its anti-inflammatory and antioxidant properties. https://www.sciencedaily.com/releases/2026/08/260824065543.htm XX New research estimates the number of people living with type 1 diabetes (T1D) worldwide will increase by 29% from 9.4 million in 2025 to 12.1 million in 2049. This will be presented at EASD, the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2 The USA will see an increase of over half a million, going from 1,492,825 to 2,055,235. The authors suggest that the reasons for the predicted high incidence and prevalence in 2049 in countries such as Australia, US, UK are likely to be a combination of genetics, environmental triggers and also high case detection rates (due to the good health care infrastructure here and in other HIC). Unlike previous estimates, the DIAMOND-T1D model takes historical patterns of insulin availability into account and aims to provide global, regional and country-specific estimates of T1D incidence, prevalence and mortality from 1900 to 2050. Although the majority of people with T1D live in high-income countries (HIC) and middle-income countries (MIC), the largest relative increase in the T1D prevalence is expected to occur in LIC as access to insulin, glucose monitoring and survival all improve in those countries. https://www.news-medical.net/news/20260828/Type-1-diabetes-cases-projected-to-increase-worldwide-by-2049.aspx XX Early initiation of statins after a diagnosis of type 2 diabetes was associated with a lower risk of dementia, according to a study published in The Lancet Regional Health – Europe. According to the Lancet Commission, nearly half of dementia cases could theoretically be prevented by eliminating 14 risk factors. "Detecting and treating high levels of low-density lipoprotein cholesterol (LDL-C) from midlife is one such highlighted risk factor," From Danish registers, researchers identified 132,585 statin-naive individuals who developed type 2 diabetes from 2006 through 2019, with follow-up until the end of 2021.   Medical records were searched for diagnoses of all-cause dementia. A clone-censor-weight design was used to analyze dementia incidence in patients with no statin initiation within five years after diagnosis, in those with early statin initiation within one year and in those with late statin initiation between one and five years after diagnosis.   https://medicalxpress.com/news/2026-08-early-statins-diagnosis-diabetes-dementia.html   XX We are heartbroken over the loss of our friend Dolly Parton. Dolly was a beloved icon whose extraordinary generosity, warmth, and compassion touched countless lives, including those of the Children's Diabetes Foundation and the Barbara Davis Center for Diabetes. Her support of The Carousel Ball and Carousel of Hope Ball reflected her deep commitment to helping children and families affected by type 1 diabetes. Beyond her remarkable talent, Dolly will be remembered for the kindness and joy she shared so generously with others. Our hearts are with her family, friends, and all who loved her as we celebrate her extraordinary life and lasting legacy. She will be deeply missed.    

Charles Brenner breaks down what the science actually says about NAD+, separating established findings from the claims commonly made in the longevity space. He explains why NAD levels in tissues may matter more than blood measurements, how metabolic stress, alcohol, inflammation, and other conditions can disrupt the NAD system, and how nicotinamide riboside (NR) compares with niacin, nicotinamide, and NMN. The conversation also covers research on exercise recovery, peripheral artery disease, skin health, infection, and wound healing, along with the limitations of current human evidence. Brenner explains why he advises against IV and subcutaneous NAD+, discusses concerns around NMN quality, and challenges popular sirtuin-centered theories of anti-aging while emphasizing the importance of reproducible human research. Charles Brenner is an NAD metabolism researcher whose work focuses on cellular bioenergetics, vitamin B3 biology, metabolic stress, and the pathways that regulate NAD production and utilization throughout the body. Now based at the University of Helsinki, his research has examined how the NAD system responds to conditions ranging from metabolic and liver disease to mitochondrial dysfunction, inflammation, and neurological stress. His work has also helped advance research into nicotinamide riboside as an NAD precursor and its potential applications in human health. Brenner takes an evidence-first approach to longevity science, distinguishing findings supported by controlled human studies from promising but still unproven mechanisms, animal research, and anecdotal claims.   Brenner Lab — Charles Brenner, PhD https://www.brennerlab.net/   Niagen NR Clinical Studies — Niagen Bioscience https://www.niagenbioscience.com/pages/clinical-studies   Nicotinamide Riboside for Peripheral Artery Disease — Mary M. McDermott et al. https://pubmed.ncbi.nlm.nih.gov/38871717/   This is the PAD study discussed in the episode where NR improved six-minute walking performance.   NOPARK: Nicotinamide Riboside in Early Parkinson's Disease — Haukeland University Hospital / Norwegian Research Team https://clinicaltrials.gov/study/NCT03568968   This is the 400-participant, 52-week Parkinson's trial discussed in the transcript.   Effects of Nicotinamide Riboside in Long COVID — Chao-Yi Wu, Edmarie Guzmán-Vélez, Charles Brenner et al. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370%2825%2900567-X/fulltext   This is the Long COVID study Brenner references when discussing cognition, fatigue, sleep, and symptom recovery.   NAD+ Metabolome in Alcohol-Related Liver Disease — Richard Parker, Charles Brenner et al. https://pubmed.ncbi.nlm.nih.gov/32766477/   This is the human alcohol-related liver disease research Brenner discusses when explaining disturbed liver NAD metabolism.   Nicotinamide for Skin-Cancer Chemoprevention — Andrew C. Chen et al. https://pubmed.ncbi.nlm.nih.gov/26488693/   This is the major Australian study relevant to Brenner's discussion of oral nicotinamide and skin cancer protection.   Charles Brenner on NAD+, NR vs. NMN & NAD IVs — Dr. Rhonda Patrick / FoundMyFitness https://www.foundmyfitness.com/episodes/charles-brenner   Dr. Mike specifically references Brenner's appearance with Rhonda Patrick during the episode.   Show Notes 00:00 Welcome to the Hart2Heart Podcast 00:58 NAD Basics Explained 02:22 Cellular Role of NAD 03:21 Proven Benefits and Trials 05:24 Inflammation Markers Deep Dive 09:19 Athletes Recovery and VO2 Max 13:52 Does NAD Decline With Age 20:10 Skin NAD and UV Damage 23:40 Who Should Take NR 27:56 Niacin vs NR vs NMN 32:28 NMN Conversion and Quality 35:37 IV and Injection Warnings 42:18 Dosing Timing and Alcohol 46:50 Addiction Claims and Dream Trials 51:39 Parkinsons and Long COVID Data 55:03 Sinclair Critique Revisited 57:05 Stacking Supplements and Metformin 59:58 Wrap Up and Where to Follow   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

Charles Brenner breaks down what the science actually says about NAD+, separating established findings from the claims commonly made in the longevity space. He explains why NAD levels in tissues may matter more than blood measurements, how metabolic stress, alcohol, inflammation, and other conditions can disrupt the NAD system, and how nicotinamide riboside (NR) compares with niacin, nicotinamide, and NMN. The conversation also covers research on exercise recovery, peripheral artery disease, skin health, infection, and wound healing, along with the limitations of current human evidence. Brenner explains why he advises against IV and subcutaneous NAD+, discusses concerns around NMN quality, and challenges popular sirtuin-centered theories of anti-aging while emphasizing the importance of reproducible human research. Charles Brenner is an NAD metabolism researcher whose work focuses on cellular bioenergetics, vitamin B3 biology, metabolic stress, and the pathways that regulate NAD production and utilization throughout the body. Now based at the University of Helsinki, his research has examined how the NAD system responds to conditions ranging from metabolic and liver disease to mitochondrial dysfunction, inflammation, and neurological stress. His work has also helped advance research into nicotinamide riboside as an NAD precursor and its potential applications in human health. Brenner takes an evidence-first approach to longevity science, distinguishing findings supported by controlled human studies from promising but still unproven mechanisms, animal research, and anecdotal claims.   Brenner Lab — Charles Brenner, PhD https://www.brennerlab.net/   Niagen NR Clinical Studies — Niagen Bioscience https://www.niagenbioscience.com/pages/clinical-studies   Nicotinamide Riboside for Peripheral Artery Disease — Mary M. McDermott et al. https://pubmed.ncbi.nlm.nih.gov/38871717/   This is the PAD study discussed in the episode where NR improved six-minute walking performance.   NOPARK: Nicotinamide Riboside in Early Parkinson's Disease — Haukeland University Hospital / Norwegian Research Team https://clinicaltrials.gov/study/NCT03568968   This is the 400-participant, 52-week Parkinson's trial discussed in the transcript.   Effects of Nicotinamide Riboside in Long COVID — Chao-Yi Wu, Edmarie Guzmán-Vélez, Charles Brenner et al. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370%2825%2900567-X/fulltext   This is the Long COVID study Brenner references when discussing cognition, fatigue, sleep, and symptom recovery.   NAD+ Metabolome in Alcohol-Related Liver Disease — Richard Parker, Charles Brenner et al. https://pubmed.ncbi.nlm.nih.gov/32766477/   This is the human alcohol-related liver disease research Brenner discusses when explaining disturbed liver NAD metabolism.   Nicotinamide for Skin-Cancer Chemoprevention — Andrew C. Chen et al. https://pubmed.ncbi.nlm.nih.gov/26488693/   This is the major Australian study relevant to Brenner's discussion of oral nicotinamide and skin cancer protection.   Charles Brenner on NAD+, NR vs. NMN & NAD IVs — Dr. Rhonda Patrick / FoundMyFitness https://www.foundmyfitness.com/episodes/charles-brenner   Dr. Mike specifically references Brenner's appearance with Rhonda Patrick during the episode.   Show Notes 00:00 Welcome to the Hart2Heart Podcast 00:58 NAD Basics Explained 02:22 Cellular Role of NAD 03:21 Proven Benefits and Trials 05:24 Inflammation Markers Deep Dive 09:19 Athletes Recovery and VO2 Max 13:52 Does NAD Decline With Age 20:10 Skin NAD and UV Damage 23:40 Who Should Take NR 27:56 Niacin vs NR vs NMN 32:28 NMN Conversion and Quality 35:37 IV and Injection Warnings 42:18 Dosing Timing and Alcohol 46:50 Addiction Claims and Dream Trials 51:39 Parkinsons and Long COVID Data 55:03 Sinclair Critique Revisited 57:05 Stacking Supplements and Metformin 59:58 Wrap Up and Where to Follow   The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart

Your eggs begin developing months before ovulation. So what can you actually do during that window to improve your egg quality? In this episode of the As a Woman podcast, reproductive endocrinologist Dr. Natalie Crawford explains the 60-to-90-day process of egg development and why age is only one part of the egg-quality conversation. She explores how nutrition, inflammation, mitochondrial health, blood sugar, sleep, stress, exercise, supplements, and environmental exposures may shape the ovarian environment during this critical window. You cannot reverse age-related changes, but understanding how an egg develops can help you focus on the factors that may be within your control. Whether you are trying to conceive, preparing for IVF, freezing your eggs, or thinking about your future fertility, this episode offers a science-backed place to start. IN THIS EPISODE: 00:00 Can You Improve Egg Quality Naturally in 90 Days? 01:45 How Many Eggs Are Women Born With? 02:23 Is Egg Quality Determined by Age? 03:32 Egg Quality vs. Egg Quantity: What Is the Difference? 03:13 How Long Does an Egg Take to Develop Before Ovulation? 04:50 When Should You Start Preparing for IVF or Egg Freezing? 05:30 What Causes Chromosomal Abnormalities in Eggs? 06:55 How Does Mitochondrial Health Affect Egg Quality? 08:04 How Are Estrogen and Progesterone Connected to Egg Health? 08:47 What Can Follicular Fluid Reveal About Egg Quality? 10:36 What Foods Help Support Egg Quality? 11:15 Do Healthy Fats Support Fertility and Hormone Health? 12:02 Which Protein Sources Are Best for Fertility? 12:47 Can Omega-3 Fatty Acids Support Egg Quality? 13:33 How Does Oxidative Stress Affect Egg Quality? 13:55 Should You Take CoQ10 for Egg Quality? 14:42 Does Vitamin D Affect Egg Quality and Implantation? 15:21 Can Melatonin Support Egg Quality? 16:22 How Do Blood Sugar and Insulin Affect Egg Quality? 17:41 How Can You Improve Insulin Sensitivity? 18:30 Can Strength Training Support Egg Quality? 19:00 Can Inositol, Metformin, or GLP-1 Medications Support Egg Quality? 19:40 How Do Sleep and Stress Affect Egg Quality? 21:02 Do Endocrine-Disrupting Chemicals Affect Egg Quality? 21:44 How Can You Reduce Endocrine-Disrupting Chemical Exposure? 23:02 What Should You Do 90 Days Before Conception, IVF, or Egg Freezing? AS A WOMAN WITH DR. NATALIE CRAWFORD: YouTube: https://youtube.com/playlist?list=PLveZDgg3_HZ9m7Wy3C6Vvyrj_NtEOwj_l  Apple Podcasts: https://podcasts.apple.com/us/podcast/as-a-woman/id1449553339  Spotify: https://open.spotify.com/show/12IYOLH9liu60gk5D0bRPk  HOST RESOURCES: Order The Fertility Formula: https://www.nataliecrawfordmd.com/book  Newsletter: https://www.nataliecrawfordmd.com/newsletter  Instagram: https://www.instagram.com/nataliecrawfordmd  YouTube: https://www.youtube.com/@NatalieCrawfordMD  Become a patient: https://www.forafertility.com  Earn FREE CE/CME: https://learnatpinnacle.com/education  This episode is brought to you by The Pinnacle Podcast Network. ABOUT DR. NATALIE CRAWFORD: Natalie Crawford, MD, is a double board-certified OB/GYN and reproductive endocrinologist, co-founder of Fora Fertility, and author of The Fertility Formula. She helps women understand their hormones, fertility, and reproductive health so they can make informed decisions about their bodies. Disclaimer: Natalie Crawford, MD, is a doctor, but she is not your doctor. This content is for general education and is not a substitute for individualized medical care. Learn more about your ad choices. Visit megaphone.fm/adchoices

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. 1:15 Our hosts speak with Katherine R. Tuttle, MD, FASN, FACP, FNKF, Executive Director of Research at Providence Inland Northwest Health and a Professor of Medicine at the University of Washington School of Medicine. She is an author of the article "SGLT2 Inhibitors for the Primary Prevention of CKD in Type 2 Diabetes: A Systematic Review and Meta-analysis," available at doi.org/10.2337/doci26-0001. 8:50 Next, Richard introduces Alexander Turchin, MD, MS, Director of Informatics Research at the Division of Endocrinology at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School. He is an author of "Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022," available for free at doi.org/10.2337/doc26-0027. 17:05 Richard and Jane highlight special material available in the latest issue of Diabetes, Obesity, and CardioMetabolic CARE. "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity—2026," available for free at doi.org/10.2337/doci26-0003 "Employment and Diabetes: A Statement of the American Diabetes Association," available for free at doi.org/10.2337/doc25-0092. 23:40 Finally, Richard and Jane highlight some of their favorite articles from the July-August issue. Vidovic, et al. Behavior Modifications From CUT-DM, Including Lifestyle Modification and Self-Efficacy doi.org/10.2337/doc25-0093 Chan, et al. Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes doi.org/10.2337/doc26-0019 Bannuru, et al. RAAS Inhibitors for the Primary Prevention of CKD in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-analysis doi.org/10.2337/doci25-0014 Dimentstein, et al. Goals of Care Among Caregivers of Youths With Type 1 Diabetes doi.org/10.2337/doc26-0035 To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

In this episode, Drs. Pradip Kamat, Monica Gray, and Rahul Damania talk through a heartbreaking case involving a 14-year-old girl with a history of psychiatric illness who intentionally took 45 tablets of metformin and empagliflozin. Things went downhill quickly—she developed severe lactic acidosis, hypoglycemia, acute kidney injury, and eventually suffered a cardiac arrest that required ECMO and continuous dialysis. Sadly, even with the most aggressive care, she didn't make it. The doctors walk listeners through the pharmacology and toxicity of metformin and empagliflozin, discuss how these drugs can cause harm, and share key management strategies. They really stress the importance of early recognition, using extracorporeal therapies, and working as a multidisciplinary team when dealing with severe pediatric overdoses of antidiabetic medications.Show Highlights:Case study of a 14-year-old girl with intentional ingestion of an oral antidiabetic agentPresentation of severe lactic acidosis, hypoglycemia, acute kidney injury, and cardiac arrestDiscussion of the pharmacology and toxicology of metformin and empagliflozinMechanisms of metformin toxicity and its effects on metabolic processesDifferentiation between types of lactic acidosis related to metforminImportance of early recognition and management of metformin toxicitySupportive care strategies for managing severe metformin overdoseRole of extracorporeal therapies, including ECMO and dialysis, in treatmentMultidisciplinary approach involving intensivists, nephrologists, and toxicologistsClinical implications and outcomes of severe metformin toxicity in pediatric patientsResources:Fuhrman & Zimmerman - Textbook of Pediatric Critical Care Chapter: Nothing foundReference 1: Noites I, Figueiredo M, Shchomak Z, Boto L, Camilo C. Fatal Pediatric Metformin-Associated Lactic Acidosis: When Severity Goes Unnoticed. Cureus. 2026 Feb 16;18(2):e103719.Reference 2: Bebarta VS, Pead J, Varney SM. Lacticemia After Acute Overdose of Metformin in an Adolescent Managed Without Intravenous Sodium Bicarbonate or Extracorporeal Therapy. Pediatr Emerg Care. 2015 Aug;31(8):589-90.

Lowering A1C in Prediabetes and Using Less Insulin on a Low-Carb Diet: Leyla Muedin, a registered dietitian nutritionist, answers listener questions about blood sugar and insulin. Responding to Rita, whose hemoglobin A1C rose from 5.6 to 5.8, Layla says “glucose hacks” to blunt carb absorption aren't appropriate at that level and recommends a strict very low-carb/keto approach (under 25 grams of total carbs per day), avoiding sugar, starchy vegetables, fruit (except avocado), sweetened beverages, and even alternative sweeteners and low-carb processed products; she suggests retesting A1C after three months and avoiding testing during illness or inflammation. She also addresses Joy, a type 1 diabetic, affirming low-carb eating to reduce insulin needs and weight gain, criticizing an insurance pricing structure that charges more when insulin is used more slowly, and expressing concern about doctors prescribing insulin too quickly for type 2 diabetes instead of dietary intervention.

For David Peters, what began as medical attention to address an enlarged prostate in 2022 became a diagnosis of Stage 4B prostate cancer.  Prior to his undergoing a Rezum procedure, a pre-op workup a PSA level of 19.  However, nobody at the hospital bothered to check the PSA level before performing the procedure, which placed David at great risk.  Not long after that came his diagnosis.  David's care team recommended lifelong androgen deprivation therapy.  He checked out the side effects and didn't want to go that route.  David instead opted for a three-week to Hope4Cancer in Cancun, Mexico, where he underwent an intense holistic regimen.  In 2026, when the cancer spread to his bones, he went to the First Nations Clinic in Tennessee, where he is undergoing a nanotherapeutics protocol.  It is keeping the cancer at bay, and he enjoys a healthy lifestyle.   David said his cancer journey did not begin with cancer symptoms.  The combination of frequent urination and a weak stream led him to believe he had an enlarged prostate and went to a doctor.  He had many options, but chose a Rezum procedure, in which steam into the prostate through the rectal wall and it shrinks the prostate.  However, the care team wanted to first make sure David didn't have prostate cancer, so he was given a PSA test.  This was in May of 2022.  In August, the surgery was performed; but it wasn't until September that a nurse informed him that his PSA level was dangerously high at 19, meaning the surgery was performed when his risk for cancer was high, but the care team didn't know it!   Not long after that, David Peters was diagnosed with Stage 4B prostate cancer, which had spread to his sacrum, iliac chain and a node near his rib cage.  His oncologist discussed with Dave various treatment options, but urged him to immediately begin a regimen of androgen deprivation therapy, which would basically shut off his testosterone.  It did not David and his wife, Kathi, to agree this was not the way to go, and they opted to see remedies that were more holistic in nature.   After some research by David and Kathi, they decided to Hope4Cancer in Mexico, where he would undergo intensive testing and holistic work.  He really appreciated that Hope4Cancer treats body, soul and spirit with an eye toward wholeness.  He experimented with a raw vegan diet and with fasting.  David ended up being more diligent about the meats and vegetables he ate.   David continued his cancer journey in February 2026 at the First Nations Clinic in Tennessee, where he began a protocol of nanotherapeutics.  They disrupt the cancer cells, and for the first time in three years his PSA went down.  He goes to the clinic once a month.   David Peters is happy to report he weighs 150 pounds, like he did in high school.  He walks every day, exercises three times and does pushups every day.   Additional Resources:   David's Website: https://www.threewordsdoc.com        

Could you please comment on the new study that finds protein restriction could slow aging?Considerations for protein intake across the lifespanMy bone mineral density has improved with strontium. Should I stop taking it?  What about vitamin K2?

Rapamycin und Metformin als Pharma-Produkte im Off-Label-Use, dazu Fisetin und Berberin als Supplements. Nehmen oder nicht? Wann und wie und wieviel davon? Wir tauchen ab in die Spezial-Kategorie der Substanzen, die in Zellgesundheit und Stoffwechsel eingreifen. Nix für Anfänger!

Reverse Type 2 Diabetes by fixing the real problem: insulin resistance and excess fat, not just “high blood sugar.” In this class, Dr. Vaughn breaks down why high-fat diets (including keto) can drive insulin resistance, why triglycerides are a crucial but ignored lab marker, and how the right foods can help you safely get off diabetes medications like insulin and metformin.You'll learn:✨ Why diabetes is not primarily a sugar problem✨ The hidden role of triglycerides and high-fat diets in insulin resistance✨ Why most diabetics are told to fear fruit (and why that's misleading)✨ A simple, realistic way of eating (vegetables, quality protein, and fruit) to support blood sugar balance✨ How faith, lifestyle, and natural strategies can help you break free from medsIf you're tired of “manage your condition forever” and want to actually address the root cause, this video is for you. To find out how we can help you on your health journey, book a free 15-minute Discovery Call with one of our New Client Coordinators! Click the link: https://www.spiritofhealthkc.com/discoverycallFor more health tips and information visit: https://www.spiritofhealthkc.com/To buy natural health supplements visit: http://store.spiritofhealthkc.comFacebook: https://www.facebook.com/SpiritofHealth/ Instagram: https://www.instagram.com/spiritofhealthkc/Pinterest: https://www.pinterest.com/spiritofhealthkc/YouTube: https://www.youtube.com/channel/UCwRcNSxR3kMYi9wP8OmxlQQ Spotify: https://open.spotify.com/show/7yfBBUjWKk3yJ3auK71O7H?si=295c77ed21f14568&nd=1&dlsi=af01c00121ed4aed

What happens if you take berberine for 30 days? Does berberine really mimic Ozempic? Discover the berberine benefits beyond weight loss, the connection between berberine and blood sugar, and why some consider it a natural Metformin. 0:00 30 days on berberine 0:20 Is berberine a Metformin alternative1:55 Berberine and Ozempic2:19 What is insulin resistance?3:15 Berberine vs. Metformin4:18 Metformin side effects5:36 Berberine benefits 6:02 Berberine dosage

In this episode of the Health Optimization Medicine Podcast, our clinical team (Dr. Ted Achacoso, Dr. Scott Sherr, Dr. Allen Bookatz, Jodi Duval, and Dr. Jup Kuipers) takes a deep dive into the shocking new 21-year pre-diabetes follow-up study (DPPOS) published in the Journal of the American Medical Association on June 15, 2026. Moving past the mainstream longevity hype surrounding Metformin as an anti-aging cure-all, the faculty breaks down why chemically poisoning your enzymes is a profound mismatch for healthy, active individuals. From the bioenergetics of exercise to the clinical application of precision metabolomics, this roundtable shifts the conversation from off-label drug prescriptions to cultivating true cellular safety and mitochondrial hormesis. Join us as we delve into: The Metformin Illusion: The long-term results of the DPPOS study proving Metformin completely failed to outperform a placebo for reducing multimorbidity risk, while intensive lifestyle intervention reduced multiple chronic disease risks by over 20%. Mitochondrial Blockade: How Metformin's inhibition of Complex I of the electron transport chain chemically throttles your cells, cutting cardiovascular fitness gains (VO2 max improvements) in half compared to exercise alone. The mTOR Obstacle: Why daily off-label Metformin use actively blunts muscle hypertrophy and strength gains in response to resistance training by blocking key adaptation pathways. The Rating of Perceived Exertion (RPE) Spike: How chemically throttling your mitochondria drives up lactic acid, leaving active biohackers with nagging, unexplained fatigue during workouts. Pathogenesis vs. Salutogenesis: Why functional and preventive medicine remain trapped in disease-centered thinking, and how Health Optimization Medicine shifts the focus to detecting and correcting cellular imbalances. The 3-Phase Metformin Transition Protocol: A step-by-step clinical sequence using early morning circadian anchors, urinary organic acid testing, targeted orthomolecular cofactors, and pulsed phytoceuticals strictly on rest days. This episode is for you if: You are currently taking Metformin or berberine off-label for anti-aging but feel like your gym gains and recovery have plateaued. You want to understand the exact biochemical mechanisms of how daily chemical inhibitors block the cellular stress signals required for exercise adaptations. You want to learn how to transition off chronic metabolic blockades and restore biological peak quality of life naturally. You can also find this episode on… YouTube: https://youtu.be/v1e132gqY_k   Find more from Health Optimization Medicine and Practice (HOMeHOPe): Website: https://homehope.org/ Instagram: https://www.instagram.com/homehopeorg/ HOMeHOPe Conference 2026: https://homehope.org/homehope-conference-2026 Use PODCAST10 to get 10% OFF your purchase of the Clinical Metabolomics Module at https://homehope.org/products/clinical-metabolomics   Find more from Troscriptions: Website: https://troscriptions.com/ Instagram: https://www.instagram.com/troscriptions/ Use POD10 to get 10% OFF your Troscriptions purchase at https://troscriptions.com/collections/our-products

Polycystic Ovarian Syndrome has been renamed Polyendocrine Metabolic Ovarian Syndrome. So seems like a good time to review our previous episode on it as we prep for a formal update on why the name change happened. Also, we hear Danielle's voice for the first time!!   Robyn Flynn joins Chris to talk about polycystic ovarian syndrome. More common than most people realize and with more far-reaching implications than it would initially seem. It can impact fertility, cardiovascular health, and according to Robyn is more painful than childbirth?!? We're going to have to look into that one.   You can also check out Robyn's podcast, Rebel Mom Boss https://open.spotify.com/show/4uMAsJS9ySR47iGYw8ExDo?si=bc68ddfcb0bd4f3f   Become a supporter of our show today either on Patreon or through PayPal! Thank you! http://www.patreon.com/thebodyofevidence/ https://www.paypal.com/donate?hosted_button_id=9QZET78JZWCZE   Email us your questions at thebodyofevidence@gmail.com.   Editor:    Robyn Flynn Theme music: “Fall of the Ocean Queen“ by Joseph Hackl Rod of Asclepius designed by Kamil J. Przybos Chris' book, Does Coffee Cause Cancer?: https://ecwpress.com/products/does-coffee-cause-cancer   Obviously, Chris not your doctor (probably). This podcast is not medical advice for you; it is what we call information.   References: 1) Dutch Twin study about the role of genetics in PCOS:   10.1210/jc.2005-1494   2) Cochrane review on meds that improve fertility https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003053.pub6/full   3) RCT of diet to restore fertility https://academic.oup.com/jcem/article-abstract/88/2/812/2845309?redirectedFrom=fulltext   4) Benefits of weight loss prior to fertility treatment 10.1210/jc.2016-1659 5) Letrozole vs. clomiphene for fertility treatment https://www.nejm.org/doi/full/10.1056/NEJMoa1313517 6) Metformin as a fertility treatment 10.1001/jamanetworkopen.2020.11995  

Thomas Mullooly is a Certified Financial Planner, Investment Adviser Representative, and President of Mullooly Asset Management, Inc. After receiving a big surprise in the form of a Type 2 Diabetes diagnosis, Thomas was determined to find a long term solution rather than accept his doctor's proclamation that he would have to take Metformin for the rest of his life. Now, 100 lbs. lighter and in the best metabolic/physical shape of his life, he's convinced he has found the solution for him.   In this episode, Dr. Brian, Dr. Tro, and Thomas talk about…   (00:00) Intro (02:27) How Thomas found out he had Type 2 Diabetes and how he discovered the key to reversing it (10:46) Intermittent fasting and the keto diet (11:46) How Thomas slowly gained weight and inched closer and closer to metabolic disease (19:02) Perseverance and success (26:37) Cold plunge and cold exposure (31:22) Breaking through weight-loss stalls (35:26) Motivation for sticking with the lifestyle changes you've committed to (43:51) Outro   For more information, please see the links below. Thank you for listening!   Links:   Please consider supporting us on Patreon: https://www.lowcarbmd.com/   Resources Mentioned in this Episode:   Thomas Mullooly: Mullooly Asset Management: https://mullooly.net/ X: https://x.com/tommullooly Linkedin: https://www.linkedin.com/in/njfinancialplanner/   Dr. Brian Lenzkes:  Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author   Dr. Tro Kalayjian:  Website: https://toward.health Twitter: https://twitter.com/DoctorTro IG: https://www.instagram.com/doctortro/   Toward Health App Join a growing community of individuals who are improving their metabolic health; together.  Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more.    Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888  Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://toward.health/community/

Vitamin B12 Deficiency--The “Aging” Symptoms You Shouldn't Ignore: Leyla Muedin, a registered dietitian nutritionist in New York City, discusses vitamin B12 deficiency as a common problem that can mimic normal aging, noting adults need only about two micrograms daily to support red blood cells, nerves, and DNA. She reviews the history of liver treatment for pernicious anemia and explains that deficiency remains common in older adults, vegans/vegetarians, and people with impaired absorption due to low stomach acid, autoimmune gastritis, weight loss surgery, or medications such as metformin and proton pump inhibitors. Symptoms can develop slowly and include fatigue, weakness, shortness of breath, numbness/tingling, poor balance, memory issues, and brain fog; she advises medical evaluation and B12 testing rather than assuming aging or relying on wellness-clinic injections when levels are normal. She emphasizes B12 is primarily in animal foods, so vegans need supplements, and notes broader nutrient shortfalls she sees in vegan clients.

This week I had my regularly schedule phone-in with syndicated radio host Michael DelGiorno. We discussed nutritional strategies for health as we age.LONGEVITY AND NUTRITION: 7-NUTRIENTS TO PAY ATTENTION TO AS YOU AGE. DR. JOE GALATI EXPLAINS…1. CalciumWhy it's needed: Keeps bones and teeth strong, helps muscles contract, and assists neurotransmitter release. As you age, the body leaches calcium from bones if you don't consume enough.Best Sources: Dairy (yogurt, cheese, milk), canned salmon/sardines with bones, kale, chia seeds, and fortified plant milks.2. Vitamin DWhy it's needed: Promotes calcium absorption and supports immune and brain health. Seniors often spend more time indoors and their skin becomes less efficient at producing Vitamin D from sunlight.Best Sources: Fatty fish (salmon, trout), egg yolks, and fortified foods like orange juice and cereals.3. Vitamin B6Why it's needed: Vital for metabolism and brain health. Older bodies break down B6 more quickly and absorb it less efficiently.Best Sources: Chickpeas (one cup provides over half the daily goal), chicken breast, bananas, and potatoes.4. Vitamin B12Why it's needed: Essential for the nervous system and red blood cell production. Roughly 10-30% of seniors have trouble absorbing B12 from food, often due to lower stomach acid or medications (like Metformin).Best Sources: Beef, seafood, and eggs. Experts recommend seniors get at least half their B12 from fortified foods (like nutritional yeast or cereals) because they are easier to absorb.5. ProteinWhy it's needed: To blunt sarcopenia(the gradual loss of muscle mass and strength). Nearly one-third of seniors do not eat enough protein.Requirements: Aim for 0.45 to 0.54 grams per pound of body weight (approx. 68–81g for a 150lb person).Best Sources: Greek yogurt, eggs, beans, tofu, and lean meats.6. FiberWhy it's needed: To prevent constipation and lower the risk of cardiovascular disease. Most seniors fall well short of the recommended intake.Requirements: Men (51+) need 30g; Women (51+) need 21g daily.Best Sources: Lentils, whole grains, berries, and leafy greens.7. Total Calories (Energy Intake)Why it's needed: Appetite often declines with age, leading to unintended weight loss and weakness.The Approach: If appetite is low, focus on nutrient-dense, high-calorie foods rather than large volumes of food.Best Strategy: Use healthy fats like olive oil, avocados, peanut butter, and full-fat dairy, or drink smoothies with protein powder to ensure energy needs are met.How To Reach Dr. Joe Galati and his Team:For an on-line consultation or press inquiries, contact Teresa Reyes at 713-794-0700Dr. Galati's Newsletter Sign-UpLiver Specialists of TexasGet a Copy of Dr. Galati's BookDr. Galati on FacebookMessage Dr. Galati and his team Hosted on Acast. See acast.com/privacy for more information.

Metformin is one of the most commonly prescribed medications for type 2 diabetes and prediabetes, but did you know it can increase the risk of vitamin B12 deficiency? In this episode, Dr Jedha explains why this happens, the symptoms to watch for, and when it's worth talking to your doctor about a simple vitamin B12 blood test.You'll also hear two inspiring member stories showing how sustainable nutrition and lifestyle changes helped improve blood sugar, lower A1c, and avoid or stop medication. Whether you're taking metformin or simply want to better understand your treatment options, this episode provides practical, evidence-based insights to help you make informed decisions about your diabetes health.For show notes and resources, please visit: https://Type2DiabetesTalk.comTo share your questions and suggestions, leave us a voice message or email at: https://Type2DiabetesTalk.com/messageExplore our proven programs and services, visit: https://Type2DiabetesTalk.com/programsSubscribe to our free weekly newsletter for podcast updates, valuable nutrition tips and more: https://Type2DiabetesTalk.com/subscribe

A Note from James:I've been obsessed with anti-aging and longevity science for a long time. I've had many longevity researchers on the podcast, but this episode feels different because something we've been discussing for years has now moved into human trials.David Sinclair first came on the show in 2019, when his book Lifespan was published. He's a professor of genetics at Harvard Medical School, and that first conversation changed how I lived. I started experimenting with intermittent fasting, paid much more attention to sleep, and began researching many of the supplements and lifestyle changes he discussed.But the most important idea David talked about wasn't a supplement. It was the possibility of reversing cellular age using Yamanaka factors—genes that can reset the instructions cells use to function. At the time, nobody knew whether this could be done safely without causing cancer or making cells lose their identities.Now, a therapy based on three of those factors has entered its first human clinical trial. The initial target is age-related damage to the optic nerve, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The trial is designed primarily to evaluate safety, but researchers will also measure visual function.David explains how this technology worked in mice and nonhuman primates, why the eye was chosen as the first organ, and how the same approach might eventually be applied to the liver, lungs, joints, skin, and brain.We also cover the practical questions people always ask him: NMN, NAD, metformin, berberine, testosterone, growth hormone, diet, fasting, sleep, exercise, and what David himself has started—or stopped—taking.This is still experimental science. Nobody yet knows whether the animal results will translate into meaningful benefits for humans. But for the first time, researchers are beginning to test that question directly.About Lifespan: Dr. David Sinclair founded Lifespan to deliver clear, science-backed health insights that help people live longer, more vibrant lives.He's now building the world's largest community dedicated to extending human longevity well beyond today's limits. Join early access at lifespan.com. New episodes of Lifespan with Dr. David Sinclair -- the #1 health and wellness podcast in its first season -- are now available on YouTube, Spotify, Apple Podcasts, and Lifespan.com.Episode Description:For years, longevity researchers have looked for ways to slow the biological processes associated with aging. Dr. David Sinclair and his collaborators are now testing a more ambitious possibility: whether damaged human cells can be restored to a younger, more functional state.The experimental therapy, ER-100, uses controlled expression of three transcription factors—OCT4, SOX2, and KLF4, collectively known as OSK. These are three of the four Yamanaka factors originally used to transform adult cells into pluripotent stem cells.Turning on all four factors can erase too much of a cell's identity and has produced tumors and fatal outcomes in animal experiments. Sinclair's team found that removing one factor, c-MYC, allowed cells to regain younger patterns of gene expression without completely returning to a stem-cell state.In preclinical studies, OSK restored youthful epigenetic patterns, promoted optic-nerve regeneration, and reversed vision loss in mouse models. Life Biosciences, a company Sinclair co-founded, has now moved the technology into a first-in-human Phase 1 trial involving people with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy.David explains how the therapy is delivered directly into the eye and activated using doxycycline, allowing clinicians to control when and for how long the genes are expressed. He also describes the development path that could follow if the treatment proves safe, including therapies targeting the liver and other organs, as well as future medicines that may reproduce similar effects without gene delivery.The conversation then turns to interventions available today. David distinguishes between promising research and claims that have moved ahead of the evidence, discussing NMN, injected NAD, growth hormone, testosterone, taurine, nattokinase, metformin, berberine, and nootropics.Throughout the episode, he emphasizes that no supplement has been shown to reproduce the effects researchers are attempting to achieve through partial epigenetic reprogramming—and that many of the most dramatic claims circulating online remain unsupported.Editorial Note:ER-100 is an investigational therapy. Authorization to begin a clinical trial does not mean the treatment has been proven safe or effective, nor has it been approved for clinical use.The Phase 1 study is primarily evaluating safety and tolerability, with additional measurements of visual function. Results from mice and nonhuman primates do not establish that the therapy will restore vision or reverse biological aging in people.The discussion of supplements, prescription medications, hormones, and lifestyle practices reflects the speakers' personal views and interpretation of the research. It should not be treated as individualized medical advice. Prescription drugs, hormones, supplements, and experimental longevity treatments should be discussed with an appropriately qualified healthcare professional.What You'll Learn:How partial epigenetic reprogramming differs from completely resetting a cell into a stem cell.Why researchers selected three Yamanaka factors—OCT4, SOX2, and KLF4—instead of using all four.What ER-100 is designed to do and why the first human trial focuses on the optic nerve.How doxycycline acts as an external switch controlling when the therapeutic genes are expressed.What Phase 1 researchers will measure and what would need to happen before ER-100 could become an approved treatment.Why the eye provides a useful starting point for testing cellular rejuvenation.What animal studies suggest about restoring vision, memory, liver function, joints, and skin.Why delivering rejuvenation therapies throughout the body is more difficult than treating one localized organ.The difference between oral NMN supplementation and intravenous or subcutaneous NAD.What current research does—and does not—show about growth hormone, testosterone, taurine, metformin, and berberine.Why muscle, exercise, sleep, diet, glucose regulation, and inflammation remain important even if rejuvenation therapies eventually succeed.How Sinclair's laboratory is searching for pills and small molecules that could mimic epigenetic reprogramming without gene therapy.Timestamped Chapters:[04:53] The First Human Trial Begins David discusses ER-100, FDA authorization, and the treatment of open-angle glaucoma and ischemic optic neuropathy.[06:52] What Are the Yamanaka Factors?How reprogramming genes can reset cellular instructions—and why using all four factors can be dangerous.[08:56] Reversing Vision Loss and Memory Problems in AnimalsDavid describes studies involving the eyes, brain, skin, kidneys, liver, and age-related cognitive decline.[10:09] Why Four Factors Can Cause CancerThe difference between restoring youthful function and erasing a cell's identity completely.[10:54] The Three-Gene BreakthroughHow Sinclair's student Yuancheng Lu persisted through years of failure and identified the OSK combination.[12:03] Pulsing the Genes vs. Leaving Them ActivatedEarlier four-factor experiments required intermittent activation, while OSK showed a different safety profile in animal eyes.[13:36] The Doxycycline Safety SwitchHow clinicians may use an antibiotic to activate and deactivate the therapy after it has been delivered.[14:51] Treating the Cause Instead of the SymptomsDavid argues that restoring younger tissue function could allow the body to repair damage associated with age-related disease.[16:02] Why the Trial Starts With the EyeLocalized delivery reduces systemic exposure and makes visual changes easier to observe and measure.[16:50] Can the Therapy Reach the Brain and the Rest of the Body?The challenges of distributing gene-based treatments evenly across organs and through the blood-brain barrier.[18:25] What the Phase 1 Trial Will MeasureSafety, tolerability, visual function, and the possibility of an accelerated development path.[20:36] Expanding Beyond GlaucomaWhy each organ may require a different delivery vehicle—and how the liver could become another early target.[21:38] How Shinya Yamanaka Found the Original Four FactorsThe trial-and-error process that turned adult cells into induced pluripotent stem cells.[22:38] How ER-100 Is DeliveredDavid explains the OSK genes, the AAV delivery system, doxycycline activation, and why manufacturing is expensive.[25:21] When Could the Treatment Become Available?David gives his most optimistic development timeline and discusses parallel programs targeting other organs.[27:31] NMN, NAD, Sirtuins, and the Information Theory of AgingHow declining NAD levels may affect cellular defenses and the regulation of gene expression.[31:34] Oral NMN vs. Injected NADWhy David believes oral supplementation currently has more rigorous evidence than NAD injections.[32:20] Longevity Misinformation OnlineDavid explains why he is restarting his show and warns against confident recommendations unsupported by research.[32:41] Growth Hormone and LifespanWhy growth hormone may improve certain functions but has not been shown to slow aging or extend human life.[34:05] Testosterone, Muscle Mass, and Healthy AgingPotential benefits for maintaining muscle—and why testosterone alone should not be considered a longevity treatment.[36:01] Taurine, Nattokinase, and Changing Your MindWhy David stopped taking taurine regularly and what prompted his interest in nattokinase.[37:30] David's Current Diet and His 86-Year-Old FatherLower meat and cheese consumption, little alcohol, exercise, supplements, and tracking inflammation through biomarkers.[39:33] James's Longevity RoutineLimited processed sugar, intermittent fasting, reduced meat and alcohol, and prioritizing eight hours of sleep.[40:07] Why Sleep Cleans the BrainThe relationship between sleep, waste removal, protein accumulation, cognition, and dementia risk.[40:33] Metformin as a Possible Longevity DrugWhy a medication developed for type 2 diabetes remains central to aging research.[41:41] Berberine and Mitochondrial FunctionWhat clinical studies suggest about glucose regulation and why David sometimes alternates berberine with metformin.[43:10] Modafinil, Adderall, and NootropicsPossible short-term benefits for focus weighed against uncertainty about long-term consequences.[43:43] What Comes After the Eye Trial?Potential applications involving the liver, lungs, kidneys, joints, brain, and other age-related conditions.[45:14] Can Rejuvenation Make Skin Look Younger?David describes unpublished work involving human skin, wound healing, and orally delivered compounds in mice.[46:17] Beyond Gene Therapy: A Rejuvenation PillHow AI and chemical screening may help reproduce the effects of early embryonic reprogramming more cheaply and simply.[47:31] When Could Chemical Reprogramming Reach Humans?David discusses the preclinical safety work and the uncertainty surrounding future human studies.[48:11] The Lifespan Community and FoundationDavid introduces his new show, longevity community, and support for scientific research.Additional Resources:ER-100 Phase 1 Trial — ClinicalTrials.govOfficial registration for the first-in-human study evaluating ER-100 in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.Life Biosciences: FDA Clearance for ER-100The company's January 2026 announcement that the FDA cleared its Investigational New Drug application.Life Biosciences: First Participant DosedThe June 2026 announcement marking the start of dosing in the Phase 1 trial.“Reprogramming to Recover Youthful Epigenetic Information and Restore Vision” — NatureThe 2020 mouse study reporting that OSK expression restored youthful epigenetic patterns, promoted nerve regeneration, and reversed vision loss.The Sinclair Lab at Harvard Medical SchoolResearch, publications, laboratory members, and information about David's work on the biology of aging.Lifespan: Why We Age—and Why We Don't Have ToDavid Sinclair and Matthew LaPlante's 2019 book about the biology of aging and emerging longevity research.LifespanDavid's longevity show, research magazine, community, and information about the Lifespan Foundation.NMN Human-Trial Review — PubMedA review of the safety evidence and proposed effects of nicotinamide mononucleotide in human clinical studies.NMN and Physical Performance — PubMedA systematic review examining randomized trials of NMN and physical-performance measurements.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode Description: Everyone is calling it nature's Ozempic. That is marketing. And it is doing a total disservice to what berberine actually does. Berberine is not a GLP-1 drug. It does not work the same way. The weight loss outcomes are not comparable. And if you are taking it expecting to drop 15% of your body weight, you are going to be disappointed. But here is what the research actually shows, and why Dr. G takes berberine every single day. The clinical evidence on berberine for blood sugar, cholesterol, insulin resistance, and gut health is genuinely compelling. A three month randomized controlled trial in newly diagnosed type two diabetics showed reductions in HbA1c, fasting blood glucose, and post-meal blood glucose that were comparable to metformin. A 2022 meta analysis confirmed it hits triglycerides, total cholesterol, LDL, blood pressure, and insulin resistance markers simultaneously. And the gut microbiome research is a piece almost nobody is talking about.In this episode, you will learn:  •  What berberine actually does in the body through the AMPK pathway, why it is not a GLP-1, and what to realistically expect from it  • Why standard berberine has a major absorption problem, what dihydroberberine is and why it may deliver 2 to 4 times more into circulation at a fraction of the dose  • Exactly how to buy berberine intelligently, what standardization means on a label, which forms to choose, and what to avoid Dr. G's recommended berberine brands linked in the show notes.Product reviews assess both brand transparency and product quality. If a company doesn't respond to our outreach, it doesn't automatically mean their product is low quality but it does mean they're failing their customers on transparency and communication. We reach out multiple times. No response isn't an oversight, it's a choice. And consumers deserve better. Timestamps: 0:00 - Intro 1:44 - How Berberine Works in the Body (And Why It's Not a GLP-1 Drug) 3:24 - The Weight Loss Reality: What Berberine Can and Can't Do 4:48 - Blood Sugar and Insulin Resistance: Where the Evidence Is Strongest 6:30 - Comparable to Metformin in Some Trials — What That Actually Means 7:42 - Cholesterol, Triglycerides & Cardiovascular Risk: Berberine's Strongest Evidence Base 9:44 - How Dr. G Uses Berberine in His Own Daily Routine 10:38 - Berberine's Underrated Effect on the Gut Microbiome 12:30 - The Big Absorption Problem With Standard Berberine (And the Solution) 14:22 - Dihydroberberine: 2-4x More Bioavailable in Human Trials 15:18 - How to Buy Berberine Intelligently: Standardization, Form & Third-Party Testing 17:00 - Who Should Take Berberine (And Who Shouldn't) Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of More Than a Pretty Face, Dr. Azi sits down with double board-certified facial plastic surgeon Dr. Amir Moradi to unpack one of the most talked-about topics in aesthetics: fillers, facelifts, biostimulators, and skin-tightening devices. Together, they break down what patients really need to know about filler migration, the "overfilled" look, Sculptra, Radiesse, RF microneedling, and when surgery may actually be the better option. This conversation cuts through the fear, misinformation, and viral opinions online to give you an honest, expert-backed look at how to age naturally, safely, and beautifully. Timeline of what was discussed: 00:00 - Introduction & Why Aesthetics Feel More Confusing Than Ever 03:00 - Are Fillers Really Preventing Future Facelifts? 04:25 - Why People in Their 30s Usually Don't Need a Facelift 05:45 - When Is Someone a Good Candidate for Fillers? 08:00 - When Is Someone Actually Ready for a Facelift? 11:15 - The Structural Changes Behind Facial Aging 15:20 - Can Botox & Fillers Delay Surgery? 18:45 - What Causes the "Overfilled" Look? 21:40 - The Truth About Filler Migration 24:45 - What Surgeons Actually See During Facelift Surgery 27:45 - Sculptra vs. Radiesse Explained 31:15 - Can Sculptra Replace Fat? 35:00 - RF Microneedling & Skin Tightening Devices 37:45 - Can Energy Devices Destroy Facial Fat? 39:35 - Lazy & Dead Cells Production  40:00 - Evidence of Peptides, mTOR, Rapamycin, Metformin 48:59 - Smash or Pass Questionnaire  ______________________________________________________________ Follow Dr. Moradi on Instagram: @MoradiMD Dr. Amir Moradi is a board-certified facial plastic and reconstructive surgeon specializing in advanced facial rejuvenation procedures, including facelifts, neck lifts, eyelid surgery, and non-surgical aesthetic treatments. Known for his natural-looking results and meticulous approach, Dr. Moradi is dedicated to helping patients achieve refreshed, balanced, and confident appearances. Learn more about Dr. Moradi's clinic: https://moradimd.com/  ______________________________________________________________ Submit your questions for the podcast to Dr. Azi on Instagram @morethanaprettyfacepodcast, @skinbydrazi, @nurselacie, on YouTube, and TikTok @skinbydrazi. Email morethanaprettyfacepodcast@gmail.com. Shop skincare at https://azimdskincare.com and learn more about the practice at https://www.lajollalaserderm.com/ The content of this podcast is for entertainment, educational, and informational purposes and does not constitute formal medical advice. © Azadeh Shirazi, MD FAAD.  

We hear a mystery tox case from Jerry Snow, director of the toxicology fellowship at Banner University Medical Center in Phoenix, and one of his med tox fellows Andrew Sheen. Learn more at the Intensive Care Academy! Takeaway pearls References PATHOPHYSIOLOGY & CLASSIFICATION 1. Lalau JD, Kajbaf F, Protti A, et al. Metformin-associated lactic acidosis … Continue reading "Episode 102: Tox files #1 with Andrew Sheen and Jerry Snow"

Is type 2 diabetes an incurable, progressive disease, as many doctors claim? The research says no. There is a simple, food-based approach that has been quietly studied since the 1970s, and it has helped people get their A1C back to normal without Metformin, without insulin, and without giving up a social life. In this episode, Chris Reade, entrepreneur and author of Beating Diabetes, shares his own story: his A1C jumped from normal to 9.1 in a single year, his doctor handed him a prescription and told him diabetes was an incurable, progressive disease. He walked out of that office and decided to find another way. Four months later, his A1C was back in the normal range. No Metformin. No insulin. No extreme diet. Listen now and start taking control of your blood sugar today! For show notes, visit https://fivejourneys.com/podcasts/soluble-fiber-may-be-your-best-tool-to-reverse-type-2-diabetes/  Follow us on Instagram at https://www.instagram.com/feelfreakingamazing/  Related Episodes Reverse Pre-Diabetes with a Fasting-Mimicking Diet, with Dr. Joseph Antoun How to Stop Taking Metformin, Insulin, and Ozempic for Good, with Dr. Jeffrey Hockings Lose Weight By Improving Your Leptin Sensitivity, with Dr. Bindiya Gandhi Lower Your Risk for Cancer & Chronic Diseases, with Dr. Greg Eckel Reverse Chronic Diseases using Allulose, with Neil Gyte Overcome 14 Chronic Illnesses, with Ashok Gupta Lose Weight By Getting Healthy, with Ben Azadi Try Keto for Optimal Health, with Robert & Crystal Sikes Leverage Ketosis and Fasting to Reverse Disease, with Ben Azadi Unlocking Longevity: Transform Your Health with a Fasting Mimicking Diet, with Dr. Joseph Antoun Why 16 Hours Isn't Enough for True Fasting Benefits, with Dr. Chris Rhodes Why Eating While Fasting Could Give You Better Results, with Renee Fitton

Dr. Deb Muth 00:02What if I told you that before a single drop of chemotherapy goes into a cancer patient’s body, we can take a blood sample, grow their actual living cancer cells in a lab, and test 70 different drugs against those cells, all outside the patient’s body, to find out which ones actually work. And what if I told you that the conventional oncology doesn’t routinely use this test? Well, today we’re going to talk about why that matters and we’re going to go through and I’m going to share a story that is very personal to me. It’s about a 38 year old man with a rare complex cancer diagnosis and the precision testing that is helping to keep that cancer from progressing. Stay with me. This is one that is going to change how you think about cancer treatment. Dr. Deb Muth 01:05You guys can put a little ad right in here before we start the next segment here. Hey everybody, welcome back to Let’s Talk Wellness Now. I’m Dr. Deb and today we’re going deep. I mean really deep. It’s some of the most cutting edge cancer testing I have ever seen in clinical practice. Now, normally I don’t talk about cancer. And I would not be sharing this story if it was anyone other than my own family. I do have permission to share and talk about this publicly. So I want to do this. I want to make sure that I share this message. And he is giving his blessing to share this story because we both believe that it can save lives. So his name is Cameron. He’s 38 years old. And he is my son-in-law. And two years ago, he came to me with a small lymph node underneath his arm and a bullseye rash. So of course, being the lime literate person that I am, my first inclination was to say, yeah, this makes sense. You have an enlarged lymph node because you have this bullseye rash. You got bit by the tick. Let’s keep an eye on it. If it doesn’t go away, let me know. So Fast forward a year and a half later, he comes to me and says, mom, what do you think about this? This thing is getting a little bit larger. And I said, yeah, it’s a little larger. Not sure. Let’s keep an eye on it. He wasn’t feeling anything. All his labs looked okay. And then one day he was out chopping wood and he started getting numbness in that arm and he felt it again. And it had exploded in size. And so after some evaluation with my daughter and him, we decided to do a ultrasound. And we thought what was going to come back was a fatty tumor. It felt like one looks like one responded to one. He’s 38 years old. He’s healthy. There’s nothing in our mind that’s ever thinking the result that we’re going to get back. Dr. Deb Muth 03:28Is a possible lymphoma. Needless to say, we were shocked by that ultrasound result. And we go fast forward, we have the biopsy. I requested a total excisional biopsy. I was told by the oncologist that that was old school. They don’t do that that way anymore. And I need to stay out of this. I need to let the experts take care of this because that’s what they do best. And this came from a breast surgeon here in Wisconsin. And so I stepped back for a moment. I let him do his biopsy and what came back was adenocarcinoma of an unknown origin. Had we excised the entire lymph node, we would have had more tissue to work with. I think we could have gotten a better diagnosis. So over the course of the next two and a half, three months, we have some more imaging done. We have some more testing done. They send a pathology out to Mayo Clinic. And what continues to come back is this incongruent test results. If anybody’s ever had this, it’s extremely frustrating. One test shows lymphoma. Now it shows breast cancer. Then the next week it shows estrogen receptor HER2 positive breast cancer. Two weeks later, another test comes back and it says, no, it’s not HER2, it’s triple negative breast cancer. And now it looks like it’s out of the lymph nodes. Now it looks like it’s in the lymph nodes. And we do a PET scan and they can’t find cancer anywhere except in this axilla area. But now we find a lymph node on the right side. So it must have spread.Let’s go ahead and do a biopsy on that. And so they biopsy the right side and the right side comes back with nothing other than tattoo ink. Now, all of this is kind of crazy. I am not a cancer specialist. I want to start by saying that I am not a cancer specialist. What I am sharing today is from a mother-in-law’s perspective, from a medical detective’s perspective, I do know how to do research. I do know how to find answers. And so what I’m going to share with you Dr. Deb Muth 05:54Is totally my opinion and totally my experience. And I’m not telling anybody to do anything different than what their doctors are telling them to do. But I am telling you to ask questions. So I go deep down the rabbit hole and find out that Tattoo Ink can appear like metastatic cancer on a PET scan. And we all know everybody gets tattoos today. They’re all over everyone. And yet we’re not thinking about how this tattoo ink can cause problems for us down the road, not to mention that there are heavy metals in them and it’s a toxin and it’s creating an inflammatory process in your body that your body’s constantly trying to get rid of. So the surgeon says to us, well, yes, that’s normal that that lymph nodes inflamed. It’s normal that there’s tattoo ink in it. The body’s doing what it’s supposed to do. It’s trying to get rid of a toxin. Okay. I will agree with that, but My son-in-law is covered with tattoos everywhere. And why didn’t we mention the tattoo ink that was found in the left axilla? We are only mentioning it in the right axilla. So there’s a lot of controversy, a lot of confusion. Many of you would never know any of this because A, you either don’t look at your lab results. And if you do, you don’t understand what you’re looking at. And that creates a problem for us, right? You don’t know what questions to ask. So we go into the doctor and the doctor tells us you have cancer and we’re going to swoop you in. And in the next two weeks, you’re going to be doing chemotherapy and radiation. And six months from now, we’re going to be doing surgery and there’s no time for questions and you’re scared shitless and you’re just doing what you can to survive. And I get that. And I totally understand that. And I appreciate that. But I’m telling you that If that is your choice, that is your choice. But as you’re doing that, take the time to ask the right questions. When this happened to us, there was a lot of challenging things with the oncology team. Nobody bothered to allow them to be a partner in their care. They dictated their care, but didn’t allow them to be a partner. So, Dr. Deb Muth 08:17Here’s what most oncologists do when patients get a cancer diagnosis. They look at the tumor type, they look at the stage, they look up the NCC guidelines, the National Comprehensive Cancer Network, and they follow the algorithm. Now, I have an enormous respect for conventional oncology. I really do. Working with cancer is probably one of the hardest things in medicine that anyone can do. The advances in this field over the last 10 years have been remarkable. But here’s my issue. Standard treatment assumes your cancer is the same as the cancer in the clinical trial that created the guidelines. It’s assuming that you and your cancer are the exact same as everyone else. You are the unique fingerprint, not the cancer. And this is the problem because your cancer is unique, just as unique as if you had your fingerprint taken, the mutations driving your tumor, the drugs your cancer cells are sensitive to, the metabolic vulnerabilities of your cancer. These are all different from the person sitting next to you in the chemo suite that has the same triple negative breast cancer or HER2 positive breast cancer or prostate cancer or colon cancer that you have. So what do do about that? Well, in my world, in the integrative medicine world, we test precisely, intelligently with the tools that most oncologists have never heard of. Or if they have, they haven’t incorporated it into their treatment modality for a variety of reasons. Either it’s not acceptable by the organization that they work for, they don’t understand it, They’re not going to be able to change their protocol anyway because they have to follow the NCCN protocol. So they don’t do it or they use a portion of it and they don’t do anything outside the protocol. So today I want to cover three things with you, three tools that we used that I think every cancer patient should be asking for when they start treatment or wherever you are in treatment at this point. Dr. Deb Muth 10:44you need to have these tests done. I don’t have any affiliation with any of these companies. I don’t get paid to tell you any of this. So let me just start by saying that I understand the chemistry behind these and how important it is to give you precision cancer treatment. And that’s why I’m talking about them today. The first one we’re going to talk about is the North Star response. This is your cancer surveillance score in the blood. How much cancer is circulating in the blood. The North Star Select, your cancer’s genomic blueprint from a blood draw. And the Datar Cancer Genetic Chemoscale, the live cell drug sensitivity test that tells us which drugs actually kill your cancer. So let’s go. Let’s dive into this. Let me just take a drink here. I’m going to cough a little bit. I apologize. I have this horrible tickle. It just never seems to go away, but that is not for today to discuss. So what is all of this? OK, the North Star response is a test that was developed by a company called Billion to One. And yes, that name is intentional because of the precision involved. It’s a next generation sequencing test, meaning it reads DNA at an incredibly detailed level. And it looks at something called methylated circulating tumor DNA or methylated CT DNA. Now let me break this down in plain English for you, because this can get a little overwhelming. When the cancer cells die or shed, they release tiny fragments of DNA into your bloodstream. We call this cell-free DNA or CFDNA, and it’s hidden within that cell-free DNA. And there are fragments that come from tumor cells. We call those CT DNA or circulating tumor DNA. Here’s what makes North Star’s response different. Rather than just looking for mutations in that tumor DNA, which is what most liquid biopsies do, and a liquid biopsy is just a blood test, Dr. Deb Muth 13:03This test looks at something called methylation patterns. Think of methylation like a dimmer switch on a gene. In healthy cells, certain genes are switched on and off in a very predictable way. In cancer cells, those dimmer switches go haywire. And cancer DNA has a characteristic hypermethylation, meaning switches are turning on and should be off or off and they should be on. And these patterns are essentially a cancer fingerprint in the blood. Now the North Star response scans more than 2000 locations in the genome for these cancer specific methylation patterns. And then it adds them all up into a single number called the tumor methylation score or TMS. So for Cameron, Cameron’s blood which was drawn on April 20th, 2026, his baseline tumor methylation score came back at 13. Now here’s the critical thing, to understand this was his baseline test, his starting point. And the real power of this test is in serial monitoring, meaning we run it again and again and again over time. And if that number goes up, the cancer activity is likely increasing. If it goes down, we’re likely suppressing the tumor activity. And if it stays flat or falls, that’s telling us that the disease is responding. So this is now in the blood. We have an actual fingerprint and every test from here forward will be compared to this number. Now let’s talk a little bit about this because I was not familiar with this test at all. I wasn’t sure what to expect. I wasn’t sure what to do with it. I did not order this test. He’s working with Inveda Medical and they are fabulous over there. I will tell you that from the beginning. This is coming from a practitioner and from a mother-in-law. They were absolutely wonderful to us. So when I saw this North Star, I didn’t know, should it be zero? Should it be a hundred? And when I talked to the doctor, he said, Dr. Deb Muth 15:29This number is actually really good. An average person walking around who’s never been diagnosed with cancer, who doesn’t have cancer, their number will be between 75 and 100. Cameron’s was 13. I think that’s fantastic. But what was the first question that went through my head? It’s probably the same question that you guys are doing. How can he have cancer with a number of 13 when it’s less than the normal average? And if we’re supposed to use this to track what’s happening with his cancer, how are we going to do that once we remove the cancer? Is this number going to go to zero? And it could possibly do that. And we may not be able to use this to track whether or not the disease is actually gone. But what we can do is use this to track over the course of his lifetime to see if the cancer cells are coming back long before we detect them on imaging. And that’s the huge part of this.So this is not a test that just anybody should go out and get because you’re worried about cancer. It is a test that should be done in somebody that is already diagnosed with cancer. So let’s start by making sure we explain that, okay? So imagine if every time your cancer cells are active and they’re shedding and they’re multiplying and they’re fighting back, they’re leaving a signature in your blood not just any signature, but a specific chemical tag that says, cancer’s here. That’s what the North Star Response Test reads. Those tags across thousands of locations and gives us a single score. So we track that score over time like a thermometer for your tumor. If it goes up, we get concerned. If it stays stable or goes down, we celebrate. And we can catch a change in the blood often months before it will show up on a scan. Pretty important when we’re talking about surveilling somebody for cancer returning, when we’re worried about it, and everybody knows the cancer patient is always worried after they get that clean bill health that something’s gonna come back, and most of the time they’re told that there is no way for them to determine that or know that from a blood test. And here is the blood test that can tell us, yes, it can. Dr. Deb Muth 17:51So I would really encourage you guys to talk to your oncologist about this. If you can’t find an oncologist that will do this, talk to an integrative cancer doctor. They will most likely be familiar with it. If not, ask them to find it for you and order it for you. So next, let’s talk about that genetic blueprint because North Star Select is a different test also by billion to one run on the same blood draw, but this one is doing something completely different. This is a comprehensive genomic liquid biopsy. Liquid biopsy just means blood tusks, meaning it’s looking for specific mutations in 84 cancer related genes, all from a blood sample, no biopsy needle, no surgery, just a blood draw. It looks for CNVS, single nucleotide variants, tiny one-letter typos in the DNA code. It looks for indels, small insertions or deletions in the DNA. It looks for copy number changes, the sections of the genomes that are duplicated or deleted. It looks at fusions. So when two genes incorrectly link together to create a dangerous hybrid, MSI status, micro satellite instability, which tells us whether immunotherapy is likely to work. And it has extraordinary sensitivity. It can detect a mutation that represents as little as 0.15 % of cell free DNA in the bloodstream. That is an almost impossibly small signal in the ocean of genetic noise. So what did this show for Cameron? This is where Cameron’s case gets clinically fascinating and where it tells the story of how his cancer is being held in check. Two major mutations were identified as actionable. One was called CRAS G12C. Dr. Deb Muth 20:11And it’s a variant-ELI fraction at 0.1%. Now, CRAS, if you’ve spent any time in integrative oncology, you’ve heard this name. CRAS is one of the most well-known oncogenes in cancer biology. Think of it like an accelerator pedal in the car. In a healthy cell, CRAS pushes the cell to grow when it receives the signal to do so. And then it stops. In cancer, crass gets stuck in the go position, like on the accelerator, foot on the accelerator, to the floor, going as fast as you can around that track, right? But it’s stuck there permanently. It doesn’t turn off and it’s supposed to be turning off. The G12C variant specifically is a mutation at a very precise location. Position 12 of the CRAS protein, where a glycine is replaced by cysteine. And this matters because CRAS G12C is now a drugable target. There are FDA approved drugs specifically designed to lock this mutation into its inactive state, essentially putting a foot on the brake. Now those are drugs like, and I’m gonna slaughter these names, Sordisib, a brand name is Lumacras, and Atacras, the brand name is Crastol. Neither is yet FDA approved for breast cancer, but they are approved for lung and colorectal cancer with CrasG2C. And Cameron’s tests identified 10 active clinical trials within a region that he could potentially qualify for with this mutation. The fact that his CRAS G12C is circulating at only 0.1%. That is a very low fraction. We call that a VAF, V-A-F, very low fraction. And it tells us something important. It means that this mutation is present in a small subclone of the tumor. It’s not the overall tumor burden. So either way, when we identify, we know it’s there. Dr. Deb Muth 22:37We can catch it and we can watch it. Now, here’s another interesting thing that we saw. His TP53 was at 0.23%. This is a tumor suppressor gene, the guardian of genome. And this gene is responsible for telling damaged cells to either repair themselves or self-destruct. And when it mutates as it is here in the position R196Q, that guardian goes off duty. The cell no longer has a reliable mechanism to prevent uncontrolled growth. So TP53 mutations are present in roughly 50 % of all human cancers. And there’s currently no FDA approved drug directly targeting the TP53 but there are clinical implications. TP53 mutant tumors may respond differently to chemotherapy and several investigational approaches, including TP53 vaccines and aurora kinase inhibitors are under active investigation. So we are seeing things happen in this part of cancer right now. Now there’s something called the VUS list and we are watching This is what we’re watching. beyond those two actionable mutations, NORSTAR Select identified what we call variants of an unknown significance, VUS, adenocarcinoma of an unknown significance, ACUP. These are mutations where we don’t yet have enough clinical evidence to determine whether they’re driving cancer or not, but we watch them. So on our mutation list was CDH1, a gene linked to hereditary gastric and lobular breast cancer, CDKN2A, a tumor suppressor cell cycle regulator, CDK12, involved in DNA repair, EGFR, ERBB, this is HER2 receptor, tyrosine kinases. Dr. Deb Muth 24:55I thought this one was pretty interesting since he had an IHC that showed a three plus HER2, but then when we confirmed it with FISH, FISH showed that was negative, but now we’re actually seeing genes expressing this HER2. So is there a HER2? Is there not a HER2? This is really important because if we don’t get these diagnoses right in cancer the first time, people will spend months and years treating the wrong type of cancer with the wrong type of medication. And this may be in part why some people do better than others. If we get it right out of the gate, they do good. If we don’t get it right out of the gate, they don’t do so good. Very important to have the actual genetic makeup of the tumor that’s growing in somebody. Now last, we have something called Notch C1, NRAS and RAF1. These are key pathway components. Now all of these were at very low baffs under 0.5%. These are just whispers, not shouts, but whispers that this cancer is excreting, but your body is listening. We have to be listening. We have to be able to watch these things and monitor these. Now here’s another note of clinical interest. It was an androgen receptor positive cancer. So also detected as a VUS.We know from tissue pathology that Cameron’s tumor was androgen receptor positive. So seeing this in circulation confirms that this AR expression of the cells are present in the bloodstream and that an anti-androgen approach remains worth considering. What that means is suppressing the testosterone. What all of you know I’m about ready to say is that I hate ever suppressing hormones, especially in a 38 year old male. That is not necessarily a good thing. So before we go suppressing hormones willy-nilly, we have to know that it’s the right thing to do. And we have to be able to combat all of the complications that are going to result of that. A 38-year-old male with no testosterone could lead to heart disease down the road, could lead to bone loss, could lead to dementia, Alzheimer’s. Not to mention the sexual side effects that are going to be present. And in a man that is very, very Dr. Deb Muth 27:20Difficult for someone to manage. So you have to be very specific and you want to be very, very diligent about what you’re doing in these cases like this. Now the MSI status was not detected. This tells us that cancer is not a microsatellite instability high, meaning that standard monotherapy may have a lower baseline response of probability and the strategic integration that we’re working with with in Vita could create an immunogenesis genicity becomes even more critical. So immunotherapy is going to be very critical in a cancer case like this and working with somebody that understands that and can carefully navigate that, especially if you have an autoimmune disease like Hashimoto’s or lupus, this is all very, very pristine and has to be looked at very carefully and done very diligently in order for somebody to do this without overstimulating that immune system and causing more problems. So when we looked at the blood and found this DNA fingerprint of the cancer cells circulating in the body, from that, what we see exactly is the genetic switches that are stuck on. They’re stuck on in the wrong position. This tells us which drugs were designed to fix exactly that problem. And it opens the door to clinical trials built for these specific mutations. It also gives us a list of things to watch for over time. And if one of those tiny little signals starts to grow, we know that cancer is gaining a ground in that area. And if it shrinks or disappears, we know we’re winning. This is like, I cannot tell you how exciting this is in the cancer world and the medical world because this is really pristine cancer therapy that we’re dealing with here. And to be able to have this is just so important to life saving events in treating cancer. So. Dr. Deb Muth 29:41Let’s talk about something called the Dittar Chemoscale. This is the battle before the battle. Okay, so I’ve saved the most remarkable test for last, and this is one from a company called Dittar Cancer Genetics. They’re based out of the UK. They are CAP and CLIA certified, which means it meets the rigorous standards required for clinical laboratory testing in the US. And this test is called the ChemoScale. And it is a live cell chemosensitivity assay. So let me explain exactly what that means because it sounds complex, but the concept is actually quite elegant. When we drew the blood from Cameron, the Dittar’s laboratory isolated what are called circulating tumor associated cells or CTACs. And these are actually living cancer cells and they’re associated cells that are traveling through his bloodstream. Excuse me. So let’s think about that for a moment. Real live cancer cells isolated from a blood draw. Those living cancer cells were placed into a lab environment and exposed to over 70 different drugs, both conventional chemotherapy agents and what we call repurposed drugs. I’ll talk more about those in a minute. The lab then measured how many of those cancer cells were killed by each drug expressed as a percentage of cell death. So the scale runs from zero to a hundred and below 25%, that drug doesn’t work well against any type of cancer in that person. Might work great in somebody else, but in that particular person’s cancer that they have, it’s not gonna work so great. Anything that’s 25 to 50 % is intermediate and above 50 % is a high response. And that’s really where Dr. Deb Muth 31:43we want to be. We want to see anything higher than 50 % because that’s a great medication that can be used to kill the cancer. This is not a theoretical test. This is not based on tumor’s genetic sequence and the computer algorithm that predicts the drug response. This is a HIS actual tumor cell being killed or not being killed in real time. That is the difference. So in traditional chemotherapy, we have our protocols. If you have triple negative breast cancer, if you have HER2 positive breast cancer, if you have prostate cancer, if you have colon cancer, here’s the protocol that you’re going to use because that’s the type of cancer you have. That’s what’s been studied. Now, the problem is most of these cancers have mutated over time, especially depending on how long they’ve been in your body, because that’s what they do to try to survive. They have to change so they can survive because your immune system’s constantly trying to kill them. And so this is a really important thing. And if we don’t take an individual into response or into our thought process when we’re creating these protocols, we may give a drug that doesn’t work at all towards that cancer and you just wasted seven cycles of chemotherapy with a drug that never would have worked in the first place or had such low resistance to it that it’s now just created side effects for you but did nothing to the cancer. And then we pull out another drug and we try that. And then we pull out another drug and we try that. Instead of us knowing precisely what we can use and what we can do. And this goes for both the conventional world and the alternative world. In the alternative world of cancer, we use things like IV vitamin C and tumeric and lately ivermectin and fenbendazole and mendendazole and all kinds of other things. And if we are not truly aware that this is going to do anything, we could be wasting somebody’s time and money. So I love that this test is available. I want to walk you through a little bit about what Dr. Deb Muth 34:01we are what we saw in our case, because I think this can make a big impact on people to ask the right questions. So this particular blood test looked at several different drugs. Cameron had sensitivity from 44 % up to 61 % on different medications. Now he was really lucky. The three main drugs that they would use to treat his cancer he had greater than a 50 % response to. So that was great. However, the drugs that were recommended for him to use out of the gate had less than 50 % activity. So he would have had one drug that was really good, one drug that was not so good. And we don’t know what the outcome would have been, right? So I think this is such an incredible, incredible test to have done. This is critical friends. I’m telling you if his oncologist had chosen the two drugs based on the general guidelines for his tumor, his cells would have largely not survived. But because we ran this test, we know. So we know to avoid the drugs that won’t work and we focus on the firepower where it really counts. So I want to also talk about this repurposed drug result because this is where it gets integrated for us. Now, this section is what I want everyone in our community, our Let’s Talk Wellness community, our members to understand. This is where conventional medicine and integrative medicine intersect in a peer-reviewed clinical validated way. So the Dittar test looks at live cancer cells against what they call repurposed drugs, meaning pharmaceuticals and natural compounds that were developed for the purposes, for other purposes, like it could be an antibiotic, it could be an herbal medicine, it could be all kinds of things, vitamins, whatever. But they have demonstrated anti-cancer activity in research. And when we’re talking about integrative medicine, this is a lot of where we get Dr. Deb Muth 36:26The integrative protocols from because these particular drug compounds are known for having anti-cancer benefits. And so that’s how integrative protocols get developed. But again, it could be just like medication, like cancer drugs. If your body doesn’t have a susceptibility to it, then you’re using a product that’s not necessarily going to work. And we all know we cannot take everything that somebody recommends just simply because it has an anti-benefit to whatever it is we’re treating. There’s only so many supplements you can take. There’s only so many things you can do before you get burnt out on taking it. We call it supplement fatigue. And so we want to be very precise with what we’re doing and target this very specific area. So one of the things that showed up really, really well for our case was artemisium, sweet wormwood. It’s an anti-malarial drug that has very potent anti-cancer effects. Now I found this extremely interesting in Cameron’s case because he does have a positive tick-borne illness called Babesia. And this is one of the things that we use to treat Babesia. The other thing I think is very interesting in this case is we are studying how parasites affect cancer these days. And that’s how Ivermectin, Fenbendazole, and Menbendazole have all gotten thrown into the treatment of cancer. And so for this drug or this herb to be sensitive to this type of cancer is really intriguing to me in the world of parasites and how parasites are truly decreasing the body’s immune system and causing cancer to grow. Another thing that worked, showed up really well for him was Valprolac acid. It’s an anti-seizure drug with HDAC inhibitor properties, and this disrupts cancer cell gene expression. There was a soy formula that showed up really well. Naltrexone, you guys have heard me talk about low dose naltrexone, LDN. This actually stimulates an endogenous opioid immune response feeling, and this drug actually showed up really well. Dr. Deb Muth 38:49Something as simple as quercetin. It’s an anti-inflammatory. This is a crass inhibitor in some studies. So this is really important. I’m sure most of you have heard about the benefits of green tea and green tea also actually has anti-angiogenic or anti-cancer benefits to it. Hydroxychloroquine, very popular drug. It’s another anti-malarial drug. So again, now we have two anti-malarial drugs that are susceptible to this type of cancer. And on top of it, he has a positive babesia test. So just saying, you got to connect the dots sometimes. You got to think outside the box sometimes. Metformin is very well known as a anti-proliferative in cancer. We use it to suppress the sugar because sugar feeds cancer. Nobody should be eating sugar if they have cancer. So this one showed up as well. And then CBD, we all know of the benefits of THC, the Rick Simpson oil, and CBD can be tested to see if that is beneficial to a particular cancer cell. This is different than THC. THC works very differently in cancer. CBD is your healthy component of it. It’s the part of the marijuana plant that does not make you high. So very important here. So now let me be very clear, because I always try to be very clear. This is not FDA approved. I’m going to repeat that. This is not FDA approved. This test is a laboratory developed test, not FDA cleared. These results represent in vitro testing, meaning in a lab, not inside the human body. And the results can differ in what we call in vivo, inside the body. And this is why I always say work with a qualified clinician who can interpret these results in full clinical context. But here’s why this matters. We now have evidence, live evidence of a cancer cell that shows sensitivities to compounds that are accessible, relatively safe, and some of which he may already be using, which some of them we were. Dr. Deb Muth 41:13We were already using some of them, which made us sit back and say, this cancer has been in there for two years. If it’s a triple negative breast cancer, it’s supposed to be an aggressive breast cancer that should have spread to a different organ already after two years. It is not, it has stayed in one spot. Also interesting in this case is that there is no breast tumor that they could find anywhere. This was all confined to the axilla into the lymph node. So to have this growing for this period of time with such a small tumor marker number, that 13 that we talked about in the North Star test originally, and to see some mutations, there’s a lot of questions to this particular case. And there are lots of questions to everybody’s cancer case. They are not all straightforward cancer cases. So this is what’s important to understand this fingerprint of these cancer cells so that you can identify exactly, exactly what’s going on and treat it exactly the correct way. Super important. So this kind of information gives us the direction in an integrative protocol. It’s not guessing. This is not eat more tumor, I can hope for the best. This is personalized tumor specific precision guided integrative oncology. It is very precise. There are several countries, several clinics like this around the country that offer this type of therapy. If it’s something that you’re interested in doing, I would encourage you to look at in Vita Medical. Hope for Cancer is another great facility. There are several great facilities around the country. Like I said, that could put together an integrative approach for you if this is something that you are thinking about doing. If you’re looking for answers, if you’re in stage four or stage three and you are not getting the results that you want to get, you want to look at a different approach. You want to do a combo approach of integrative medicine and traditional medicine and alternative medicine. Dr. Deb Muth 43:37I think this is so important to look at and have experts on your team. You know, in our case, Cameron’s cancer is very complex. It’s genomically aggressive in its presentation, yet it’s not progressing to distant areas, which is so wonderful. And I want to be careful here. I can’t tell you with certainty that this is any one thing. Biology is complex. Cancer is adaptive. It’s trying to survive. That’s what it is supposed to do. It is changing its shape. It’s changing its genetic structure. It’s changing everything to try to survive and try to hide against your immune system. Now we are not even close to the finish line in our journey, but what I can tell you is that what the integrative precision approach has done that standard care alone might not do. I can tell you that today and I will share our journey along the way for any of you that are going through this that want to look at a different approach as well because I think it’s important to have this information. So first of all, we know the tumor’s fingerprint. North Star response gives us that TMS score. so we can track it over time. And if the cancer tries to gain ground, we’ll see it in the blood before a scan, we’ll show it. We know the cancer’s genetic vulnerability. We know how to handle the DNA now. We know the watch list of things to look for. And when those signals start to grow, we have a roadmap of how to address it next, how to change it. We know which drugs will automatically work against the tumor cells. We’re not guessing based on a tumor type. We tested the cells. We know how many drugs in the commercial world and in the repurposed world will and will not work. And this is going to guide the treatment protocol that we walk forward with. So we’re not giving him drugs that won’t work or have a low response. Dr. Deb Muth 45:55We’re avoiding them completely and that matters because every ineffective drug is a dose of toxicity with no benefit. There is no lie to this. Chemotherapeutic drugs are toxic. That’s how they kill the cells, but they kill the good cells and the bad cells. And if we can avoid using a drug that’s not going to work, that is so important. And then we’re layering in those repurposed and natural compounds with proven activity against specific cells. This is not complementary fluff. This is biologically active tumor tested precision medicine. Very, very important. So here is what I need you all to know and what I want you to walk away with today. If you or someone you love is facing a cancer diagnosis before treatment starts, before the first infusion goes in, I want you to ask these questions so quick. Go grab something to write with. Pause this if you need to, because this is really, really important for you to do that. And we’re going to take a break for just a second while you guys go and do that. We’re going to give you a word from our sponsor, and then we’re going to come back. And I’m going to give you the four questions that I want you to ask specifically of your medical team so that you have the answers and the ammunition that you need to work with. So we’ll be right back. Dr. Deb Muth 47:29All right, everybody, welcome back. I hope you got your pencil, your paper, your pen, your phone, whatever you’re going to take notes with because this is important. So I’m to give you four questions that I want you to ask your medical team before you get started. Question one, can we do a chemo sensitivity test before we choose a chemotherapy regime? Ask specifically about DATAR, D-A-T-A-R. cancer genetics, Oncostat Plus, or a similar functional chemosensitivity platform. Very, very important to ask those specific things. All right, question two. Can we do a comprehensive liquid biopsy to identify actionable mutations and monitor tumor burden? Ask about North Star Select, Billion to One, Guardian 360, or Foundation One Liquid CDX? I’m gonna say those for you one more time, because I said them kind of fast. North Star Select by Billion to One, Guardian 360 or Foundation One Liquid CDX? Okay, question three. Can we establish a baseline tumor methylation score, TMS, so we have a surveillance marker to track over time? and ask specifically about the North Star Response Test. All right, question four. Is there an integrative oncology center that can layer precision guided natural compounds alongside conventional treatment? Research institutes like Inveda Medical Center, CTA CA Integrative Medicine, or Hope for Cancer, these people are doing integrative medical miracles. Let me tell you, I have researched every one of them. I have spoken to each of them individually before we made our decision of who we were going to work with. They are all fantastic. You want to work with an integrative nurse practitioner who understands oncology. And if you’re working with an integrative practitioner, you want to ask them these same questions about this test so that you can get the best outcome. Dr. Deb Muth 49:56For what you’re dealing with. You are allowed to ask these questions. You are allowed to want more information from that protocol that was designed for the average patient. You’re not average and your cancer is not average either. And your care doesn’t have to be. You do not have to settle for the same thing that the person sitting next to you in the IV suite is dealing with when you both have different cancers excreting different genetic material. This is so incredibly important. want to make sure you understand precision medicine is what changes the lives for people every single day, every single day. So I started this episode by telling you about a 38 year old man with a cancer that baffled conventional medicine and integrative medicine, an occult primary that was not found complex genetic genomic profile, a presentation that in many hands might have resulted in a one size fits all treatment protocol and a prayer. And instead we ran the tests, we mapped the fingerprint, we watched the cells, we guided the protocol, and we are still fighting with precision, with data, with intelligence. This is what Let’s Talk Wellness is all about not giving up. This is what not accepting we don’t know as a final answer and demanding the level of scrutiny and personalization that every cancer patient deserves. So if this episode resonates with you, please share it because somewhere out there, there is a person who is about to get the wrong chemotherapy because no one ran the right test. And maybe, just maybe, that This episode will be the reason someone asks the right question at the right moment. If you’re going through something like this, you need a group, you need somebody to connect with, please join our free Facebook group called Seen At Last. It is where we support one another, we share this information, we share knowledge, and we help people for free support and ask the right questions. Dr. Deb Muth 52:23And if you’re inclined in your heart to pray, pray for Cameron, we could use every ounce of prayer. If you are in a position where you can help support this journey financially, we do have a fund going in free funder. I can post the link below. Every little bit helps. If you have $5, $500, it doesn’t matter. We’re raising money for this treatment. And along the way, I am documenting every step of what we’re going through so I can provide more episodes like this for you guys to share the outcome and share what our journey is like so that it can help the next person along. I really always believe that whatever happens to us happens to us because we’re meant to share it. That’s why I’ve shared my personal journey. I’m sharing his personal journey and we want to help other people. So until next time, I’m Dr. Deb. Keep asking questions, keep advocating, and never ever accept being unseen.The post Episode 274 – Stop Guessing on Chemotherapy: The Live Cell Test Most Doctors Miss first appeared on Let's Talk Wellness Now.

You are not doing the heavy lifting alone anymore.If you are living with symptoms that seem confusing, inconsistent, or flat-out exhausting, we have a vital surprise for you. For years, the Lichen Sclerosus Support Network (LSSN) has been a dedicated sanctuary for the LS community. But we know that many of our brothers and sisters are also navigating the painful, isolating world of Lichen Planus (LP) without a clear place to call home. Today, that completely changes. LSSN is officially expanding our mission to build a dedicated resource home for Lichen Planus. Joining host Kathy to launch this new frontier is Dr. Erin Foster, a leading mucosal specialist from Oregon Health & Science University. Dr. Foster is stepping up as the head of our brand-new LP department to help turn scattered search spirals into hard clinical research, clearer tracking tools, and real community hope. Visit our new LP website at https://aboutlichenplanus.comWhat You Will Learn: Core Episode TakeawaysThe Blueprint of Lichen Planus: How this autoimmune response targets the deep T-cells of your body, and why it can show up across your skin, mouth, scalp, nails, esophagus, or genitals. The Diagnostic Blur (LS vs. LP): Why classic textbook definitions are outdated. Dr. Foster shares why hyperkeratotic LP can present as completely white patches on the vulva, mimicking lichen sclerosus perfectly and causing years of misdiagnosis. The 3-to-9 Month Medication Trigger Window: A look at how common everyday medications like Ibuprofen, Metformin, and Beta-blockers can set off a delayed immune flare-up months after your first dose. The Truth About Scarring: Why identifying symptoms early in areas like the scalp (LPP) or moist mucosal tissues is vital to halt irreversible tissue fusion and hair loss. The Systemic Escalation Ladder: A breakdown of how treatments look when topical steroid creams aren't enough, including safe pills like Hydroxychloroquine and immune modulators like Methotrexate. *Self-Advocacy & Educational Use Only. This podcast episode and its accompanying notes exist to organize personal observations, validate patient experiences, and support informed conversations with your care team. This content does not diagnose medical conditions, replace formal clinical examinations, or determine medication directives. LichenS Support Network does not provide clinical diagnoses or official treatment plans. Please coordinate directly with a qualified, licensed professional for all medical evaluations, physical tissue biopsies, and therapeutic care strategies.

The World Cup is here, and while we watch some of the world's greatest athletes competing on a global stage, it's fascinating to consider what effect this intense activity may have on the human body. With that in mind, we're re-releasing our conversation with Stanford biochemist Jonathan Long on the future of exercise. Jonathan studies the chemistry of what happens inside your body when you move, and his findings are pointing toward some genuinely surprising possibilities — including treatments for obesity, diabetes, and even, someday, an exercise pill. If the athleticism on the pitch has you feeling inspired, this one is well worth another listen. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Jonathan Long Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Jonathan Long, a professor of pathology from Stanford University. (00:02:02) Effective Weight Loss Drugs The history and development of GLP-1 receptor agonists. (00:04:04) Understanding Metabolism and Exercise Why Long's lab starts with molecules to understand metabolism and physical activity. (00:05:10) Animal Models in Exercise Studies The use of animal models in exercise studies and the discovery of Lac-Phe. (00:06:47) Psychological Preparation for Exercise The psychological aspects of exercise and the involvement of endocannabinoids in exercise motivation. (00:09:00) Lac-Phe's Role and Mechanism The role of Lac-Phe and its production in the gut. (00:12:08) Differences in Exercise Response Differences in exercise response between trained athletes and untrained individuals. (00:12:57) Diabetes and Metabolic Diseases The relationship between diabetes, exercise, and metabolic diseases. (00:15:01) Lac-Phe as a Potential Therapeutic The potential of Lac-Phe as a weight loss drug, and parallels to GLP-1 drug development. (00:16:21) Importance of How Weight is Lost Whether the method of weight loss matters, and the importance of preserving lean muscle mass. (00:18:37) Exercise as Medicine The concept of exercise as medicine, and defining physical activity at the same resolution as modern medicines. (00:22:11) Metformin and Exercise Pathways The unexpected connection between metformin and the Lac-Phe pathway. (00:24:01) Prospects of an Exercise Pill The future of an exercise pill, and the challenges associated with its development. (00:27:05) Conclusion Final thoughts on the future of exercise. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode Phil Vella, founder of Vita Bella, returns to break down the wild west of the gray market peptide industry. He shares new data showing 70 percent of research peptides now fail purity and contamination testing, why so many random people are running peptide side hustles out of their garages, and the real risks of injection site infections and improperly dosed products. They cover why hormone optimization should always come before peptides, the most popular peptides Vita Bella prescribes, the science behind PDE5 inhibitors for both performance and longevity, and the regulatory battle between big pharma and compounding pharmacies over GLP medications. Phil also opens up about a brutal stretch of his life that included losing his father, a double spinal fusion injury, and nine people from his childhood neighborhood dying by suicide within about a year, and how that period reshaped his understanding of money, purpose, and fatherhood. Vita Bella / MP Hormones: https://mphormones.com Go to mphormones.com and BOOK A COMPLIMENTARY 10 minute consultation with a membership specialist to find out if Vita Bella is right for you. Or use code mindpump365 to start your annual membership and get your free blood panel and Gift. Consultation entry: https://meetings-na2.hubspot.com/alever/marketing-membership-consultation?uuid=ff3ae3e9-7828-4d4b-be06-7d8d68ba2929 SPONSORS Troscriptions: https://troscriptions.com/MINDPUMP Code: MINDPUMP for 10% off your first order. Medical grade supplements including methylene blue and Calm. MAPS Anabolic Relaunch: https://mapsanabolic.com Code: ANABOLIC for 50% off through the end of the month. Includes updated female blueprints, updated FAQ and phase overview videos, masterclass videos on the barbell squat, bench press, overhead press, barbell good morning and behind the neck press, and three days of live coaching with one of the Mind Pump coaches. LINKS Mind Pump Store: https://mindpumpstore.com Maps Fitness Products: https://mapsfitnessproducts.com Instagram: @mindpumpmedia 0:00 - Intro 3:07 - Phil Vella returns to talk peptide industry quality and regulation 5:04 - 70 percent of research peptides now fail purity testing 7:26 - Everyday people running peptide side hustles out of their homes 10:39 - Contamination, infection, and dosing risks from research peptides 13:12 - The difference between FDA regulated compounding pharmacies and the gray market 16:23 - Why hormones must be dialed in before starting peptides 19:12 - Testosterone for women and the most prescribed hormones at Vita Bella 22:04 - Recent changes to peptide regulation and the FDA review process 33:06 - Blood Pump and PDE5 inhibitors for performance, pumps, and longevity 38:22 - The Glow and Clo peptide stacks for recovery and skin health 43:15 - Metformin and glutathione as part of a longevity stack 51:11 - Phil's double spinal fusion injury and recovery 52:46 - Losing his father and nine people from his neighborhood to suicide in one year 58:11 - Moving to Bali and rebuilding his sense of purpose 1:00:38 - The Bell Curve of Happiness and why money stops buying happiness 1:09:04 - The membership model behind Vita Bella and future plans for the company

Medical professor at Duquesne University Dr. Marguerite Duane and FACTS About Fertility executive director join Trending with Timmerie: Episode Guide PCOS name changed to Polyendocrine Metabolic Ovarian Syndrome (PMOS)(2:00) Use progesterone long-term as a cancer prevention? For PCOS now PMOS (16:00) Which fertility method do you recommend, Marquette or Clearblue? (24:20) Metformin for PCOS? (26:57) Male infertility (29:15) Alex cooper is Pregnant (43:00). Resources mentioned: Dr. Duane’s website: https://www.factsaboutfertility.org/ Physician-Clincian Educator Directory: https://www.factsaboutfertility.org/facts-physician-clinician-educator-directory/ Marquette Method Instructors: https://www.marquettemethod.com/instructors/ More marquette Method Instructors https://www.mmnfp.com/instructors https://mycatholicdoctor.com/ Raising Testosterone with Sal di Stefano: https://omny.fm/shows/trending-with-timmerie-catholic-principles-applied/how-to-increase-testosterone-1 The Happy Girl’s Guide to Being Whole: What You Never Knew about Your Natural Body: https://www.amazon.com/Happy-Girls-Guide-Being-Whole/dp/1735223727 Ultimate Girls & Guys Body Books: https://www.rainbowresource.com/ultimate-girls-guys-body-books IFS Study shows you're healthier and happier when you marry https://ifstudies.org/blog/does-marriage-really-make-us-healthier-and-happier

Episode 2808 - In this information-dense and wide-ranging episode, Ted and Austin Broer connect landmark natural diabetes research, 5G neurological damage documentation, Israel's systematic destruction of Lebanese civilian infrastructure, obesity-driven cognitive decline, and a coming global whey protein shortage into one of their most practically valuable and geopolitically urgent broadcasts in recent memory. The episode opens with Austin presenting an extraordinary stack of natural insulin resistance reversal research covering eight documented compounds including curcumin, Dihydro Berberine, cinnamon extract, ginger, black seed oil, olive leaf extract, berries, and spirulina. The curcumin data stands out as particularly striking, with a 2009 study showing it to be 500 to 100,000 times more effective than Metformin at activating glucose uptake and a separate clinical trial demonstrating 100% prevention of type 2 diabetes onset in prediabetic patients over nine months.

Your cells start failing at 35. Dr Sandra Kaufmann reveals the 7 systems breaking down — and how to stop it. Your cells start failing at 35. Dr Sandra Kaufmann reveals the 7 systems breaking down — and how to stop it.

Send us Fan MailYour supplement shelf can turn into a silent monthly subscription, and the scariest part is not the cost. It's the uncertainty. We sit down to unpack why supplements so often feel like a black box, how isolated nutrients can behave differently than nutrients in whole foods, and what a sensible, evidence-based supplement routine looks like when you care about real outcomes like strength, metabolic health, energy, and long-term resilience. We walk through the decision filters we use as clinicians, starting with the most straightforward case: measured deficiencies you can actually track, like vitamin B12 or vitamin D. From there, we share John's “Four I's” checklist (imbalance, insufficiency, infection, isolation) and why the food matrix matters so much when you're deciding between a capsule and a plate. We also get specific about common scenarios, including vegan and plant-based nutrient gaps (especially zinc and B12), aging and fatty acid needs, and why omega-3 fish oil studies can look mixed compared with the consistent benefits of eating oily fish. We dig into risks that don't get enough airtime, including supplement overload, vitamin toxicosis concerns, and medication-driven nutrient depletion. Metformin and B12, statins and CoQ10, and proton pump inhibitors and mineral absorption all come up, along with a bigger theme: changing a biomarker is not the same as improving an outcome. To keep things grounded, we share what we actually take right now, why creatine has one of the strongest evidence bases in sports nutrition and healthy aging, how creatinine lab values can be misread, and where berberine and targeted probiotics like Akkermansia may fit for metabolic health when paired with lifestyle changes. We close with practical tips on supplement quality and third-party testing, plus how to build a short-term “bridge” plan with clear stop rules. Subscribe for more evidence-based self-care, share this with someone whose cabinet is overflowing, and if you found this helpful, leave a review and tell us what supplement you want us to break down next. For video recording and open source reference articles: www.thehealthedgepodcast.com

Cancer has long been understood through a variety of biological frameworks, including genetic mutations, dysregulated signaling pathways, and uncontrolled cell proliferation. Yet, these models often capture the visible consequences of disease rather than the deeper metabolic dependencies that sustain tumor survival. Despite major advances in targeted therapies, a central challenge remains: what underlying mechanisms make cancer cells vulnerable to treatment, and how can these vulnerabilities be exploited more effectively? Increasing attention has shifted toward cellular metabolism—particularly lipid regulation and energy-sensing pathways such as AMPK—as critical determinants of tumor behavior. Scientists are now taking a closer look at how metabolism works together with stress responses like autophagy—and how this connection could be used to develop better cancer treatments. A new research paper was published in Volume 17 of Oncotarget, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.” The study was led by first author Michael R. Booth and corresponding author Paul Dent from Virginia Commonwealth University, in collaboration with Laurence Booth and Jane L. Roberts from Virginia Commonwealth University and John M. Kirkwood from the University of Pittsburgh Cancer Institute. Full blog - https://www.oncotarget.org/2026/04/21/scd1-inhibition-strategy-shows-potent-synergy-with-regorafenib-and-metformin-in-tumor-cell-killing/ Paper DOI - https://doi.org/10.18632/oncotarget.28861 Correspondence to - Paul Dent - paul.dent@vcuhealth.org Abstract video - https://www.youtube.com/watch?v=lmX_c2e_-HY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28861 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, macroautophagy, ER stress, aramchol, regorafenib, BID To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Website: ⁠⁠⁠https://hunterwilliamshealth.com/⁠⁠Get my FREE Cheatsheet: ⁠https://hunterwilliamshealth.com/peptidecheatsheet⁠Join My Private Group: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://theaxioncollective.manus.space/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Get My Book On Amazon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://a.co/d/avbaV48Download⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Supplement Sources: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamssupplements.carrd.co/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Amazon Storefront: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DY⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Socials:Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/hunterwilliamscoaching/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Video Topic Request: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://hunterwilliamsvideotopic.carrd.co/⁠⁠⁠⁠⁠Today I'm breaking down something that's been blowing up in the peptide world. The FDA just made a major announcement about moving 19 popular peptides from Category 2 to Category 1. And I want to share my honest thoughts on what this actually means for you.First I walk through how we got here. The Biden administration's original scheduling decision. The rise of the research peptide market. And why roughly four out of five peptides consumed in the US today come from research companies.Then I get into what the FDA is actually proposing. The July hearing. The February 2027 timeline. And what Category 1 status would mean for compounding pharmacies and telehealth clinics.But here's where it gets interesting. I share my prediction on where prices are headed and why I think we'll eventually see price parity between prescribed and research peptides. I also dig into what I think is a quiet quid pro quo happening between Big Pharma and the FDA around GLP-1s.This is speculation on my part. I'm not a doctor or a lawyer. But I wanted to give you my honest read on where this is all going. Let me know your thoughts in the comments.Timestamps00:00 — Intro and disclaimers (not a doctor, not a lawyer)01:40 — History: How the Biden FDA scheduled 19 peptides as Category 202:44 — The rise of the research peptide gray market (4 out of 5 peptides)04:18 — RFK on Joe Rogan and the FDA's Category 1 plans04:58 — What Category 1 actually means (Sermorelin example)05:42 — The July hearing and February 2027 final say timeline07:18 — FDA cracking down on GLP-1s from research companies08:42 — More compounding pharmacies and telehealth clinics entering the space09:08 — The Metformin analogy and future price parity13:20 — The rug pull theory: FDA and Big Pharma quid pro quo on GLP-1s14:04 — Why Eli Lilly is protecting retatrutide (projected $50B/year product)17:04 — Final thoughts and the golden age of peptides

Hour 3 for 4/8/26 Dr. Sean O'Mara joins Drew to discuss GLP-1s and their associated risks (5:20). Topics/calls: reduced motivation for life (12:56), Keto + GLP-1 combo (17:14), veteran on GLP-1s (20:56), Metformin (28:24), limited dose (34:07), fermented foods (36:39), toxicity (43:22), natural strategies (45:22), not gaining weight (46:40). Links: https://drseanomara.com/ https://x.com/DrSeanOMara

In his weekly clinical update, Dr. Griffin and Vincent Racaniello cover if the "five-second" rule for things that fall on the floor apply to surgical equipment, an outbreak of E. coli illness caused by raw cheese before Dr. Griffin then deep dives into the measles outbreak in South Carolina and Utah, recent statistics RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, strain selection for the 2026-2027 season influenza vaccine by the FDA, if standard or high dose influenza vaccination influences dementia protection, a new variant of SARS-CoV-2, how to access and pay for Paxlovid, specific effects of Paxlovid and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode The "five-second" rule for dropped food: does it apply to dropped medical objects in the operating room? A randomized study of disinfection approaches for contaminated arthroplasty implants (Infection Control & Hospital Epidemiology) Whole Genome Sequencing (WGS) Program (FDA) Outbreak Investigation of E. coli O157:H7: Raw Cheddar Cheese (March 2026) (FDA) Wastewater for norovirus (WasterWater Scan) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) UtahMeasles Dashboard (Utah Department of Health and Human Services) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles(CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Risk of Alzheimer Dementia After High-Dose vs Standard-Dose Influenza Vaccination (Neurology) Weekly surveillance report: clift notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Respiratory Diseases (Yale School of Public Health) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Respiratory viral infections prime accelerated lung cancer growth (Cell) Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2 — Worldwide, November 2024–February 2026 (CDC: MMWR) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) UnderstandingCoverageOptions (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Paxlovid shows organ-specific and age-specific impacts on risk of developing post-acute sequelae of COVID-19 (Communications Medicine) The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID (Annals of Internal Medicine) Reaching out to US house representative Letters read on TWiV 1310 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

BUFFALO, NY – March 31, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on March 27, 2026, titled “The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.” Led by Michael R. Booth, Laurence Booth, and Jane L. Roberts from Virginia Commonwealth University, with corresponding author Paul Dent from the same institution and John M. Kirkwood from the University of Pittsburgh Cancer Institute, the study examines how aramchol interacts with regorafenib and metformin to kill tumor cells, particularly patient-derived uveal melanoma (UM) cells and cholangiocarcinoma cells. The authors report that aramchol, regorafenib, and metformin interact to enhance tumor cell killing, with the strongest effects seen when metformin is added to aramchol plus regorafenib. In patient-derived UM cells and LD-1 cholangiocarcinoma cells, the three-drug combination increased autophagosome formation and autophagic flux, while knockdown of Beclin1, ATG5, or LAMP2 reduced autophagosome and autolysosome formation and lowered cell killing. The study also found that BID contributes to the lethal response, supporting a multifactorial mechanism involving macroautophagy and death-receptor signaling. “Our data demonstrates that UM cells are killed by treatment with aramchol plus regorafenib plus metformin via enhanced autophagic flux and that this combination may have the potential to control UM tumors that have metastasized to the liver.” The authors also note that while SCD1 knockdown increased baseline tumor cell death, it did not replicate the full anticancer effects of aramchol, suggesting additional molecular targets contribute to its activity. They emphasize the need for further in vivo studies to evaluate the therapeutic potential of this combination in metastatic uveal melanoma, particularly in liver-targeted disease. DOI - https://doi.org/10.18632/oncotarget.28861 Correspondence to - Paul Dent - paul.dent@vcuhealth.org Abstract video - https://www.youtube.com/watch?v=lmX_c2e_-HY Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28861 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, macroautophagy, ER stress, aramchol, regorafenib, BID To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dietitians Torwen Eerkens and Aidan Muir deep dive on berberine, an emerging supplement dubbed 'Nature's Metformin'. Torwen and Aidan examine the potential benefits, risks and practical implications.  (1:40) - Diabetes Management   (2:48) - Effect on Cholesterol   (3:49) - Weight Management (6:03) - Fatty Liver Disease (7:16) - How to Take Berberine (9:30) - Potential Side Effects & Impracticalities of Berberine WEBSITE:  https://www.idealnutrition.com.au/ PODCAST:  https://www.idealnutrition.com.au/podcast/ INSTAGRAM:  https://www.instagram.com/idealnutrition__/?hl=en Our dietitians

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Metformin may help stem macular degeneration, retatutride moves forward, T1D and demntia link studied, lots of news from ATTD and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who's in Vegas? I'll see you there at the Breakthrough T1D summit this weekend. And we have two Club 1921 events for health care providers and patient leaders happening in April – head on over to the website for more. Okay.. our top story this week: XX Metformin may be linked to the slower progression of age-related macular degeneration (AMD). Among people with diabetes who were older than 55, those taking metformin had a 37% lower chance of developing intermediate AMD over a five-year period compared with individuals who were not using the medication. It's one of the leading causes of vision loss in the US and many other western countries. These researchers now say a clinical trial is the next step. https://scitechdaily.com/scientists-discover-surprising-eye-benefit-of-widely-used-diabetes-drug/ XX new study suggests people with type 1 diabetes may be nearly three times as likely to develop dementia compared with people without diabetes. Similarly, people with type 2 diabetes may have roughly twice the risk of dementia compared with those without diabetes. However, the study found an association rather than proof of causation, meaning diabetes was linked to dementia risk but was not shown to directly cause it.   https://www.usnews.com/news/health-news/articles/2026-03-19/both-types-of-diabetes-increase-dementia-risk XX Researchers in Japan say they've developed an insulin pill… in mice.  The study, published in the journal Molecular Pharmaceutics, tested the delivery of oral insulin by building a carrier peptide called DNP-V. This peptide helps to transport insulin through the small intestine, where protein drug absorption is usually poor. The result was a rapid and significant drop in blood glucose, as well as a sustained (longer-term) decrease. The mice's blood sugar was reduced to near-normal levels. Although the researchers are optimistic about the findings translating to larger therapeutic models, they noted that the results in mice do not guarantee the same outcome in humans, and that more research is needed. https://www.foxnews.com/health/needle-free-diabetes-management-could-horizon-study-suggests   XX   Lilly says it's next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients. The drug lowered hemoglobin A1C by an average of 1.7% to 2% across different doses at 40 weeks compared with placebo, and helped patients lose an average of 16.8% of their weight. Retatrutide also met the study's second goal, helping patients at the highest dose lose an average of 16.8% of their weight, or 36.6 pounds, at 40 weeks, when evaluating only patients who stayed on the drug. When analyzing all participants, including those who discontinued treatment, the highest dose of the drug helped patients lose 15.3% of their weight. The company was also "very pleased" with the relatively low discontinuation rates due to side effects, which were up to 5%, he added. But Lilly has yet to file for approval of the drug for obesity or diabetes. The company expects to report findings from seven additional phase three trials on the drug by the end of the year. Still, retatrutide's A1C reduction doesn't appear to be the greatest Lilly has seen within its portfolio: The highest dose of Zepbound lowered the measure by more than 2% at 40 weeks in two separate trials on diabetes patients. Dubbed the "triple G" drug, retatrutide works by mimicking three hunger-regulating hormones – GLP-1, GIP and glucagon – rather than just one or two like existing treatments. That appears to have more potent effects on a person's appetite and satisfaction with food than other treatments.   https://www.cnbc.com/2026/03/19/eli-lillys-obesity-drug-retatrutide-clears-late-stage-diabetes-trial.html XX   The MiniMed Flex gets FDA approval. Thi is a new design from the company formerly known as Medtronic. It's about half the size* of the MiniMed™ 780G pump, no screen – smartphone controlled – and has the SmartGuard™ algorithm with Meal Detection™ technolog. At commercial launch, MiniMed Flex™ will support the company's newest sensor portfolio, including Simplera Sync™ sensor and the Instinct sensor, made by Abbott. MiniMed also announced the MiniMed™ Forward Program, which allows customers who start on the MiniMed™ 780G system to upgrade to the MiniMed Flex™ system for $0. MiniMed Flex™ is cleared for individuals ages 7 and older with type 1 diabetes, and for individuals 18 years and older with insulin-requiring type 2 diabetes. https://www.prnewswire.com/news-releases/minimed-announces-fda-clearance-of-minimed-flex-the-companys-smallest-insulin-pump-featuring-its-first-smartphone-controlled-design-302716864.html   XX Lots of new out of the recent ATTD conference.. some headlines: New study from the UK shows that Ketone Monitoring Could Significantly Reduce DKA Risks in people with type 1 and type 2. This was a study by Abbott which recently submitted a continuous dual glucose-ketone monitor to the FDA for clearance – if approved, it could be available in the U.S. later this year. -- The first modified insulin producing cells are still working 14 months after transplant – without the need for immunosuppressive drugs. This is from Sana which now plans a study of a new therapy.. same gene-editing strategy with lab-grown, stem-cell-derived insulin-producing cells. -- Protein looks like it helps avoid lows during exercise. Both high and low doses of whey protein before exercise were effective, significantly reducing the risk of hypoglycemia by five to 10 times.   Researchers noted that the body's response to protein was rapid (within 20 minutes), which suggests taking it close to the beginning of exercise could be beneficial for preventing hypoglycemia. Though more research is needed, there was also evidence showing protein intake could be beneficial for prolonged fasting and preventing overnight lows. -- More info about type 1 and GLP medications. Researchers at ATTD presented the results of a small, seven-month study assessing the effectiveness of semaglutide for people with type 1 diabetes and obesity. During the trial, 36% of participants taking semaglutide spent more than 70% of their time in range, less than 4% of their time below range, and lost more than 5% of their body weight compared to those not taking semaglutide.   Treatment with semaglutide was also associated with reductions in cholesterol and blood pressure. Based on all of these changes, the researchers calculated that the participants who received semaglutide had significantly reduced their risk of heart disease over the next 10 years.   Other studies show that since 2020, prescriptions of GLP-1 medications have grown exponentially for adults with type 1 diabetes between the ages of 18 and 85. https://diatribe.org/diabetes-research/top-diabetes-news-attd-2026   XX Lots of talk about fully closed loops.. CamDiab unveiled theirs.. called Liberty.. which the company says it's the world's first fully closed loop commercial launch. CamDiab offers the FDA-approved mylife CamAPS FX app for automating insulin delivery in MyLife's (formerly Ypsomed Diabetes Care's) insulin delivery pumps. The mylife CamAPS FX on iOS has full compatibility with leading continuous glucose monitors (CGMs). Those include the FreeStyle Libre 3 and Libre 3 Plus from Abbott and the Dexcom G6 so customers can use their preferred device. https://www.drugdeliverybusiness.com/camdiab-unveils-fully-closed-loop-insulin-feature/ XX Insulet reported data on a fully closed-loop automated insulin delivery system in people with Type 2 diabetes. The 24 people in the trial spent 24% more time in the target blood glucose range using the system than when receiving standard injection therapy. Insulet plans to start a pivotal study this year and aims to launch in 2028. Rival insulin pump manufacturer Tandem is on a similar course. Tandem CEO John Sheridan told investors on an earnings call last month that his team plans to start a pivotal trial this year to support a filing with the Food and Drug Administration in 2027. Medtronic disclosed the start of a pivotal trial of its Vivera fully closed-loop algorithm last month, shortly before spinning off the program as part of the MiniMed initial public offering. The algorithm, which is designed to eliminate carb counting and manual food bolusing, achieved a mean time in range of 73.8% without manual user input in a feasibility study.   https://www.medtechdive.com/news/insulet-posts-clinical-data-on-fully-closed-loop-insulin-delivery-system/814516/ XX Congrats to all honored by the 2026 National Scientific and Health Care Achievement Awards from the American Diabetes Association! Shout out to Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES: 2026 Outstanding Educator in Diabetes Award and to  Korey Hood who receives the Richard Rubin award. Dr. Rubin was a pioneer in behavioral science and committed to keeping the person with diabetes at the center of research and care.

Peter Cummings is a preventive health practitioner and endurance sports coach with more than 30 years of experience helping people improve metabolic health through exercise, nutrition, and lifestyle change. A Metabolic Health Practitioner (MHP) and Nutrition Network Practitioner (NNP), he specializes in therapeutic carbohydrate reduction, cardiorespiratory fitness, and personalized exercise prescription. Cummings has authored peer-reviewed research in the American Journal of Preventive Medicine – FOCUS and has helped train health professionals to integrate fitness and lifestyle interventions into clinical care. In addition to his work in preventive medicine, he has coached athletes to multiple national and state championship titles, bringing a data-driven approach to both human performance and chronic disease prevention.    In this episode, Dr. Tro, Dr. Brian and Peter talk about… (00:00) Intro (01:56) VOT Max (04:19) Health Ballistics (Peter's new book!) (10:00) Bridging the gap between medicine and exercise (16:59) Berberine and Metformin (19:45) Helping people turn their health around and reverse diabetes (29:12) Cardiac rehab (34:43) Interval training (39:21) Carbs and exercise (42:56) Conflicts of interest in exercise science (45:45) The biggest barriers to systemic change in the fields of exercise science and nutrition (48:07) Tim Noakes' Central Governor Theory (55:09) Exercise physiology and fat burning (01:04:51) Peter's new book, Health Ballistics (01:09:35) Outro   For more information, please see the links below. Thank you for listening!   Links:   Please consider supporting us on Patreon: https://www.lowcarbmd.com/   Peter Cummings: Plan 2 Peak: https://www.plan2peak.com/ IG: https://www.instagram.com/coachcumm/ Linktree: https://linktr.ee/plan2peak?   Dr. Brian Lenzkes:  Website: https://arizonametabolichealth.com/ Twitter: https://twitter.com/BrianLenzkes?ref_src=twsrc^google|twcamp^serp|twgr^author   Dr. Tro Kalayjian:  Website: https://toward.health Twitter: https://twitter.com/DoctorTro IG: https://www.instagram.com/doctortro/   Toward Health App Join a growing community of individuals who are improving their metabolic health; together.  Get started at your own pace with a self-guided curriculum developed by Dr. Tro and his care team, community chat, weekly meetings, courses, challenges, message boards and more.    Apple: https://apps.apple.com/us/app/doctor-tro/id1588693888  Google: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.doctortro&hl=en_US&gl=US Learn more: https://toward.health/community/

Full Show Notes: bengreenfieldlife.com/498 In this solosode I kick off by talking about whether isometric training is worth your time, covering both my own fitness habits and the newest research, particularly for runners and joint health. I also unpack a buzzworthy study on how just 10 minutes of vigorous exercise daily can be a powerful longevity booster compared to longer, lighter workouts. I share why I no longer personally use metformin, and instead, offer my favorite natural alternatives for better blood sugar control—like berberine, fiber, cinnamon, and simple routines like salads and walks. Plus, I get into brain health, explaining the roles of ketones, methylene blue, and near-infrared light for cognitive performance and protecting against issues like Alzheimer’s. At the end, I answer listener questions on optimizing DHT levels, natural insulin-sensitizers, and keeping your hair healthy even if you’re on testosterone. If you’re interested in practical strategies and learning what’s currently working in my own routine, you’ll enjoy this episode. Episode Sponsors: Hiya: Give your kids the full-body nourishment they need to grow into healthy adults. I’ve secured a special deal with Hiya on their best-selling children's vitamin—get 50% off your first order today! To claim this deal, you must go to hiyahealth.com/BEN (it is not available on their regular website). BASED Bodyworks: BASED Bodyworks is a clean, plant-based men's grooming brand offering simple, high-performance essentials from shampoo and skincare to styling, formulated without harsh sulfates or hormone-disrupting chemicals, so you can look and feel your best without compromising your health. Visit basedbodyworks.com and use code BOUNDLESSLIFE for 20% off. Manukora: You haven’t tasted or seen honey like this before - so indulge and try some honey with superpowers from Manukora. If you head to manukora.com/ben or use code BEN, you’ll automatically get $25 off your Starter Kit. Apollo: Apollo is a safe and non-invasive wearable that actively improves your sleep. Head over to apolloneuro.com/bengreenfield and use code BENGREENFIELD for $90 off.See omnystudio.com/listener for privacy information.

If you're tired of taking handfuls of diabetes medications every day and watching your health decline anyway, this episode is for you! What if you could get off insulin, Metformin, Ozempic, and all your other diabetes meds while actually lowering your blood sugar? Sounds impossible, right? But it's not only possible, it's happening for thousands of people right now. And that could include you! In this episode, Dr. Jeffrey Hockings, founder and CEO of Diabetes Reversal Group, reveals the patented protocol that's helped over 10,000 people completely reverse type 2 diabetes and get off all their medications. Dr. Hockings shares the exact foods, supplements, and lifestyle strategies that work, plus real patient stories, like a man who went from taking over 300 units of insulin daily to zero medications in just six months. Listen to this episode and start your journey to medication-free health today! For show notes, visit https://fivejourneys.com/podcasts/how-to-stop-taking-metformin-insulin-and-ozempic-for-good/  Follow us on Instagram at https://www.instagram.com/feelfreakingamazing/  Related Episodes Reverse Pre-Diabetes with a Fasting-Mimicking Diet, with Dr. Joseph Antoun Reverse Chronic Diseases using Allulose, with Neil Gyte Lose Weight By Improving Your Leptin Sensitivity, with Dr. Bindiya Gandhi Lose Weight By Getting Healthy, with Ben Azadi

In today's episode, we're talking about cardiovascular health. Heart disease remains the #1 threat to the quality and quantity of life for Americans. And this is not because of a metformin or statin deficiency. We are pumping these drugs out at all time highs, but have yet to make a dent in heart disease. If you are in the traditional medicinal model, you may not be privy to the fact that there are other ways of supporting and invigorating the cardiovascular system and the underlying drivers of heart disease. You can actually improve cholesterol balance, blood sugar, arterial inflammation, and vascular health with natural means. Let's talk about where to start. Two fruit extracts that can help are bergamot and amla. You know I am a big fan of fruit and these two in particular positively influence: LDL cholesterol Triglycerides HDL Insulin sensitivity Arterial stiffness Vascular Oxidative stress You can find these two science-backed fruit extracts in Cardio Supreme.   -------- Connect with Dr. Matt online:  

Are medications solving the root of metabolic disease — or just masking it? In this powerful episode that started as a Instagram LIVE, I break down what you're not being told about the most commonly prescribed drugs for blood sugar, cholesterol, and weight loss: GLP-1s (Ozempic, Wegovy), statins, and Metformin. I help you unpack: What these medications actually do (mechanisms of action) The real data behind their risk reduction claims How statins may suppress natural GLP-1 production Why GLP-1s cause significant muscle loss, not just fat loss Why Metformin doesn't reverse insulin resistance More importantly, I walk you through what does restore metabolic health — including a system that's helping real people normalize labs, lose weight, and feel better without long-term prescriptions. What You'll Learn: The surprising truth about how statins impact your gut hormones Why insulin resistance — not cholesterol — is the real root cause How GLP-1 drugs work and what happens when you stop them The 3-step system to support blood sugar and cholesterol naturally How to evaluate your labs beyond A1C and LDL Resources Mentioned: Join my 90-Day Insulin Reset: Comment RESET on Instagram or Facebook and I'll DM you the link- https://shanahussinwellness.com/programs-courses/reset/ Feel Great Nutraceuticals: The first step to restoring insulin and liver function- https://shanahussinwellness.com/programs-courses/feelgreat/ Connect with Shana: Instagram: @shana.hussin.rdn Website: shanahussinwellness.com Facebook: Shana Hussin Wellness

Have you ever heard of inositol? Could you be deficient and not even realize it? If you're struggling with blood sugar swings, irregular cycles, anxiety, or 2am wake-ups, could this overlooked compound be a missing piece? While magnesium, B vitamins, and electrolytes dominate most wellness conversations, myo-inositol plays a critical role in insulin signaling, ovarian function, and neurotransmitter balance, acting as an intracellular messenger that helps your cells properly respond to hormonal cues. This episode unpacks what myo-inositol actually is, how it functions in the body, and what the research shows in areas like PCOS, insulin resistance, fertility, mood disorders, and sleep. It also covers therapeutic dosing, food sources, and how to use supplementation strategically for clinical outcomes. Whether you're navigating hormone imbalance, metabolic dysfunction, or nervous system dysregulation, this conversation takes a deeper look at why myo-inositol deserves far more attention in root-cause medicine. Also in this episode: What is inositol? What does it do in the body? What causes myoinositol deficiency? Symptoms of deficiency Episode 470: SSRIs on the Rise: Concerns and Safer alternatives Episode 430: Keto and PCOS Inositol and Metabolic Health Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome | New England Journal of Medicine Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial - PubMed Potential role and therapeutic interests of myo-inositol in metabolic diseases - PubMed Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials - PMC  Myoinositol vs. Metformin in Women with Polycystic Ovary Syndrome: A Randomized Controlled Clinical Trial - PMC The Comparative Effects of Myo-Inositol and Metformin Therapy on the Clinical and Biochemical Parameters of Women of Normal Weight Suffering from Polycystic Ovary Syndrome Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials - PubMed Full article: Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial The effects of inositol supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials Inositol for Mental Health Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder - PubMed Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder - PubMed Inositol treatment of obsessive-compulsive disorder - PubMed D-Chiro inositol vs. Myoinositol Food sources of inositol Dosage, safety and tolerability 1-2 scoops Relax and Regulate  This episode is sponsored by Naturally Nourished Relax and Regulate Relax & Regulate has always been a superstar for sleep, stress, and hormone support, and we've taken a good thing and made it even better! We've seen incredible results with 1000's of clients using Relax and Regulate literally every day for 10+ years now.    We have increased magnesium bisglycinate from 200 mg to 250 mg to match clinical sleep research dosing, kept myo-inositol at the full 4-gram therapeutic dose, and improved the supporting ingredients so the entire formula is better absorbed, better tolerated, and more aligned with what we're seeing clinically every day. Use code RELAX15 to save 15% on our reformulated Relax and Regulate! 

In his weekly clinical update during Ground hog week, Dr. Griffin and Vincent Racaniello are back to discuss the measles outbreak in South Carolina, American Academy of Pediatrics vaccine recommendations and shingles vaccine and the reduction of dementia, then deep dives into recent statistics RSV, influenza and SARS-CoV-2 infections, the Wastewater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, how to access and pay for Paxlovid, estimated effectiveness of this year's COVID-19 vaccine, long COVID treatment center, where to go for answers to your long COVID questions, long COVID in children, the potential benefits of metformin to reduce disease severity following SARS-CoV-2 infection in obese and overweight patients and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Grading the groundhogs (National Oceanic and Atmospheric Administration) Sand Mountain Sam predicts an early spring (News19) All About the AAP Recommended Immunization Schedule (healthychildren.org) Recommended Childhood and Adolescent Immunization Schedule: United States, 2026: Policy Statement (American Academy of Pediatrics: Pediatrics) Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments (LANCET: Neurology) Detection of avian flu antibodies in Dutch dairy cow: ECDC risk assessment remains unchanged (European Centre for Disease Prevention and Control) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard(South Carolina Department of Public Health) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles(CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Estimated Effectiveness of 2024-2025 COVID-19 Vaccination Against Severe COVID-19 (JAMA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulationguidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study (LANCET: Infectious Diseases) Long COVID is here to stay—even in children (LANCET: Infectious Diseases) Early administration of neutralising monoclonal antibodies and post-acute sequelae of COVID-19 (International Journal of Infectious Diseases) Preventing Long COVID With Metformin (CID) Metformin may reduce risk of long COVID by 64% in overweight or obese adults (CIDRAP) Effect of Metformin on the Risk of Post-coronavirus Disease 2019 Condition Among Individuals With Overweight or Obese (CID) Preventing Long COVID With Metformin (CID) New review highlights growing evidence that diabetes drug metformin can prevent long COVID (CIDRAP) Reaching out to US house representative Letters read on TWiV 1294 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Pre-Order The Forever Strong PLAYBOOK and receive exclusive bonuses: https://drgabriellelyon.com/playbook/Want ad-free episodes, exclusives and access to community Q&As? Subscribe to Forever Strong Insider: https://foreverstrong.supercast.comAre your immune cells aging faster than you are? In this episode, Dr. Gabrielle Lyon sits down with Dr. Anurag Singh, a leading physician-researcher and Chief Medical Officer at Timeline, to discuss a groundbreaking discovery: the gut-muscle-immune axis. While we often focus on muscle mass for longevity, new research published in Nature Aging reveals that our immune system undergoes a similar decline, with youthful sentinel cells (naive CD8 T-cells) dropping by 75% as we reach age 50. Dr. Singh explains how mitophagy —the targeted recycling of damaged mitochondria—is the key to "rewiring" an aging immune system to fight infection 20% more effectively. In this episode: Alzheimer's of the Muscle: Why sporadic inclusion body myositis (sIBM) is often misdiagnosed as simple aging. The Power of Urolithin A: How this postbiotic compound induces mitophagy to increase mitochondrial abundance by 20% in just 28 days. Immune Imprinting: Why children get 6-8 colds a year while adults only average 2-4. Repurposing Longevity Drugs: Dr. Singh's take on Metformin, Rapamycin, and GLP-1s for life extension. The 1:1 Exercise Rule:Why 150 minutes of moderate activity is the threshold for mitochondrial biogenesis. Thank you to our sponsors: BodyHealth - Use the code LYON 20 to get 20% off your first order https://www.bodyhealthaffiliates.com/73L4QL3/7XDN2/ Timeline - Get 35% off a Mitopure subscription at https://www.timeline.com/drlyon Manukora - Go to https://www.MANUKORA.com/DRLYON to save 31% plus $25 worth of free gifts. Chapters: 0:00 - Can You Tell If Your Immune System Is Healthy? 1:37 - Alzheimer's of the Muscle: Muscle-Immune Dysfunction 5:59 - The Thymus Design Flaw: Why Our Immune "Ammo" Disappears 8:44 - Naive CD8 T-Cells: The Elite Forces of Immunity 12:24 - The Axis of Aging: Mitochondria and Immune Cells in Muscle 16:15 - Mitophagy vs. Autophagy: Targeted Cellular Recycling 19:11 - Study Review: Rewiring the Immune System with Urolithin A 24:13 - Mitochondrial Remodeling: Switching from Glucose to Fatty Acids 27:45 - The Trifecta: Gut-Muscle-Immune Axis Connection 31:13 - Parkinson's and the PINK1/Parkin Mitophagy Pathway 35:04 - Clinical Results: Improving Leg Strength in 4 Months 38:51 - Joint Health: Can We Remodel Cartilage with Mitophagy? 43:34 - Targeted Mitophagy Inducers: Exercise vs. Postbiotics 46:44 - Precision Nutrition: The Ideal Muscle Longevity Supplement 53:33 - Why Alzheimer's is Now Considered an Inflammatory Disease 1:00:13 - The Placebo Effect: You Cannot Deceive the Immune System 1:03:13 - Lymphocyte Counts: The Clinical Marker for Immune Aging 1:08:14 - Rapamycin and Metformin: The Future of Longevity Drugs 1:11:42 - Optimal Dosing: Why 1,000mg of Urolithin A is the Standard 1:15:13 - Sports Medicine: Reducing Muscle Damage Markers (Creatine Kinase) 1:20:03 - The Final Frontier: Brain Aging and Selenium Repair Connect with Dr. Anurag Singh Instagram: @timeline_longevity Website: https://www.timeline.comFind Dr. Gabrielle Lyon at: Instagram:@drgabriellelyon TikTok: @drgabriellelyon

Metformin is a widely prescribed Type 2 diabetes drug that works by lowering liver glucose production and improve insulin sensitivity A 16-week Rutgers trial in 72 adults found that metformin dulled exercise benefits, reducing the usual improvements in aerobic fitness Long-term risks for prolonged metformin use include vitamin B12 deficiency, rare lactic acidosis, and hypoglycemia Skipping breakfast, not getting enough sleep, consuming too much alcohol, and social isolation can greatly disturb glucose regulation and increase the risk of developing diabetes over time Lifestyle strategies such as consistent movement, and a bioenergetic, nutrient-dense diet can support insulin sensitivity. Berberine may also help to slowly wean you off metformin medication

In this Huberman Lab Essentials episode, my guest is Dr. Kyle Gillett, MD, a dual board-certified physician in family medicine and obesity medicine and an expert in optimizing hormone levels to improve overall health. We explain how to improve hormone levels across the lifespan in both men and women using behavioral, nutritional and exercise-based tools. We also discuss common clinical topics, including hormone testing, PCOS, hair loss, testosterone replacement therapy (TRT) and peptides, focusing on potential benefits, tradeoffs and risks. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AG1: https://drinkag1.com/huberman Maui Nui: https://mauinuivenison.com/huberman Function: https://functionhealth.com/huberman Timestamps (00:00:00) Kyle Gillett (00:00:36) Hormone Health; Women vs Men, Tool: Hormone Testing (00:02:35) Tool: Big 6 Lifestyle Pillars to Optimize Hormone Health (00:04:32) Sponsor: AG1 (00:06:17) Diet, Individualization; Bloodwork & Frequency (00:07:20) Exercise, Zone 2 Cardio; Caloric Restriction (00:08:36) Intermittent Fasting, Growth Hormone, IGF-1 (00:11:05) Hormones & Sleep, Growth Hormone, Menopause, Andropause, TRT (00:13:28) Testosterone & Women, SHGB (00:15:19) Sponsor: Maui Nui (00:16:34) Dihydrotestosterone (DHT), Androgens; Turmeric & Black Pepper; Hair Loss (00:19:47) Polycystic Ovarian Syndrome (PCOS), Symptoms, Metformin, Inositol (00:23:13) Cannabis, Alcohol, Testosterone (00:24:48) Males & Testosterone, TRT, Prostate Cancer (00:26:04) Prolactin, Dopamine "Wave Pool", Tool: Casein & Gluten (00:27:23) Sponsor: Function (00:29:03) Social Relationships & Hormones, Tool: Planning for Crisis (00:31:02) Peptides, Growth Hormone & Risk; BPC 157, Sourcing & LPS (00:36:42) Melanotan, Uses & Risks (00:38:45) Spiritual Health, Interdisciplinary Health Integration (00:41:23) Caffeine & Hormones, Sleep; Acknowledgements Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices

My guest is Dr. Thaïs Aliabadi, MD, board-certified OB/GYN, surgeon and leading expert in women's health. We discuss polycystic ovary syndrome (PCOS) and endometriosis, two very common yet frequently undiagnosed causes of female infertility. Dr. Aliabadi explains the symptoms, underlying causes and evidence-based treatments for both conditions, including supplement and lifestyle interventions. We also discuss breast cancer risk and screening, pregnancy, perimenopause and menopause, and the hormone tests that women should request. This conversation offers empowering, potentially life-changing information for women of all ages to take control of their hormone, reproductive and overall health. Read the episode show notes at hubermanlab.com. Thank you to our sponsors AGZ by AG1: https://drinkagz.com/huberman Lingo: https://hellolingo.com/huberman Our Place: https://fromourplace.com/huberman Joovv: https://joovv.com/huberman LMNT: https://drinklmnt.com/huberman Function: https://functionhealth.com/huberman Timestamps 00:00 Thaïs Aliabadi 02:56 Why Endometriosis & Polycystic Ovary Syndrome (PCOS) Go Undiagnosed 08:16 Infertility, Tool: Early Screening 10:54 Sponsors: Lingo & Our Place 14:07 Women's Health Education Gap 15:24 PCOS Overview: Symptoms, Diagnosis, AMH, Disordered Eating 21:28 Irregular Periods, Teenage PCOS Diagnosis 24:36 Diagnosis, Pelvic Ultrasound; PCOS Naming 27:49 Thinning Hair & Acne; 4 PCOS Phenotypes; Mood & Treatment 35:54 Underlying Pillars of PCOS; HPA Axis, Androgens, Menstruation & Ovulation 40:30 Insulin Resistance & PCOS, Visceral Fat & Inflammation 46:30 Sponsors: AGZ by AG1 & Joovv 49:10 PCOS, Chronic Inflammation, Genetics & Lifestyle; Mood 52:31 PCOS, Fertility, Freezing Eggs, Tool: Egg Count & AMH Range By Age 58:34 Women's Health Education, AI, Clinicians; Cataracts Analogy 1:01:20 Stress; PCOS Treatment, Birth Control, Insulin Resistance & Metformin 1:06:44 PCOS Risk Calculator, Supplements, Lifestyle Factors; GLP-1s 1:12:32 Berberine, Metformin; GLP-1s, Food Anxiety & Alcohol 1:19:13 PCOS Prescriptions & Fertility; PCOS Co-Occurrence with Endometriosis 1:21:56 Sponsor: LMNT 1:23:16 PCOS Treatment, Freezing Eggs, Egg Quality; Advocate For Your Health 1:32:02 PCOS Key Takeaways: Symptoms, Tests, Supplements & Lifestyle 1:36:03 Undiagnosed Endometriosis, Fertility 1:39:26 Endometriosis: Symptoms, Diagnosis, Painful Periods, Infertility 1:42:30 Male vs Female Health Issues, Undiagnosed Endometriosis 1:47:01 Inflammation, Ectopic Implants, Chronic Pelvic Pain; Adenomyosis 1:50:36 Egg Quality, Endometriosis, Tools: Egg Counts; Pelvic Ultrasound 1:54:29 Sponsor: Function 1:56:13 Pain & Health Testing, Tool: Endometriosis Symptoms, Screening & Tests 2:01:32 Treatment, Surgery, Different Types of Endometriosis 2:05:22 Endometriosis Causes, Inflammation; Incidence, PCOS 2:11:58 Obstetrics & Gynecology Separation, Surgery 2:16:00 Endometriosis Key Takeaways: Symptoms, Treatment & Diagnosis 2:17:04 Treatment, Estrogen & Progesterone, Birth Control, GnRH Antagonists 2:22:39 Endometriosis Stage & Pain, Endometriosis Types 2:23:49 Pregnancy; Postpartum Depression, Menopause; Frustration for Patients 2:29:55 Fibroids, Surgery, Uterine Septum, Tool: Pelvic Ultrasound 2:34:05 Tool: Assessing Your & Partner's Fertility; Autoimmune Conditions 2:37:51 Breast Cancer, Tool: Lifetime Risk Calculator & Breast Imaging; Mastectomy 2:49:47 Endometriosis Tests, Autoimmune Disease; Brain Fog & Menopause; Inositol 2:53:06 Undiagnosed Infertility; PMDD Treatment; Fasting & Low-Carbohydrate Diets 2:57:21 Hair Loss & Perimenopause; Egg Quality; Endometriosis & Menopause 3:00:40 Increase Progesterone; Diet, Hormone & Menopause; Prolong Fertility 3:04:54 Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter Disclaimer & Disclosures Learn more about your ad choices. Visit megaphone.fm/adchoices